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Peptide library screening and binding surface mutagenesis are effective tools in early-stage 
drug development that give critical insights for evaluating biologic interactions. Prior to later-
stage chemistry, manufacturing, and controls (CMC), biologic potency depends on modulating 
key amino acid residues affecting the affinity of the potential drug towards its target(s). 
Developing biologics is thus increasingly dependent on high-throughput screening (HTS) 
techniques that accommodate rapid iteration of many candidates. Here, I synthesized a small 
library of epitope peptides derived from therapeutic targets and conducted a series of 
fluorescence anisotropy-based screens against RPtag: a novel, super-stable, antibody-like 
protein scaffold with pM binding affinity. I demonstrated tunability of RPtag and highlight its 
potential as a novel biologic by increasing affinity towards PD-L1 peptide by orders of 
magnitude. Finally, I used surface plasmon resonance (SPR) to demonstrate binding between a 
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CHAPTER 1: INTRODUCTION 
 
1.1 Principles of Biologic Therapeutics 
 
Biopharmaceuticals, or biologics, are among some of the most prolific advances of the 
modern era. Biologics are a broad category of medicines which contain components isolated 
from, or are produced directly by living organisms. Oftentimes, biologics are engineered 
proteins, commonly based on native or existing biomolecules, and are designed to elicit a 
specific therapeutic response in vivo. To date, most non-vaccine biologics are based on 
antibodies: specialized immune proteins which are generated and tailored to specifically bind 
pre-programmed targets, or antigens, with high specificity and affinity. Recently, monoclonal 
antibodies (mAbs) have been engineered by humans to specifically bind disease-causing 
antigens in a therapeutic manner, representing arguably the most significant medical advance of 
the 20th century. Since the first clinical mAb, Muromonab-CD3, was approved by the FDA in 
1986 for treating the rejection of transplanted kidneys, more than 80 mAbs have appeared on 
the market to treat a broad array of cancers, autoimmune disorders, infectious diseases, and 
age-related disorders.1,2 The success of clinical mAbs can be partly attributed to their potency, 
arising from high specificity and affinity towards their targets thanks to the highly-evolved 
structure of antibodies. Clinically, this potency decreases the risk for off-target interactions, thus 
minimizing undesirable side effects when compared to traditional, small molecule drugs.3,4 In 
addition, clinical mAbs have a long serum half-life (~7-23 days, dependent on concentration and 
isotype),5,6 and can enhance host immunity via Fcγ receptor signaling pathways.7,8 The 
bivalency of antibodies allows for increased antigen-binding capacity, and in some cases, can 
mediate the targeting of multiple antigens (i.e. bispecific).9 Finally, the modularity of antibodies 
makes them well-suited for clinical applications. By altering residues in the antigen-binding 
regions (Fab), mAb affinities can be tuned appropriately while maintaining the clinically 
desirable pharmacokinetic and immune-signaling properties of the Fc region.  
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1.2 Drawbacks of Clinical Antibodies 
 
The successes of clinical mAbs has begun to highlight their pitfalls, however. One 
significant hurdle is a high cost of production: complex post-translational glycosylation patterns 
often limits mAb production to slow-growing mammalian cultures, which require highly regulated 
and expensive manufacturing systems.10 Additionally, antibodies are large (IgG M.W. ~ 150 
kDa), and have a complex tertiary structure: IgG isotypes which are commonly used for clinical 
mAb products (IgG1, IgG2, and IgG4) require an intricate network of 16-18 disulfide bridges for 
maintaining a proper conformation.11–14 In practice, many clinical antibodies will begin to lose 
activity after several weeks in aqueous storage at 2-8°C and several days at room 
temperature.13 This severely limits deployment of mAbs in remote and developing areas where 
existing cold-chain practices are inadequate for distributing temperature-sensitive drugs.15 The 
disadvantages of clinical antibodies have spurred many to investigate alternative, non-antibody 
biologic scaffolds which retain mAb-like affinity and specificity, but are associated with a lower 
cost of production arising from yeast or E. coli expression, and increased stability due to smaller 
size. Similar to mAbs, the fundamental ADMET properties of a scaffold are unlikely to change 
significantly after minor mutational changes to binding domains.16 Non-antibody scaffolds have 
gained popularity over the past decade, with many in ongoing clinical trials and several 
approvals to date. Among the list are Adnectins,17 Affibodies,18 Anticalins,19–22 Avimers,23,24 
Designed Ankyrin Repeat Proteins (DARPins),25,26 Fynomers,27 Knottins,28 Kunitz domains, 29,30 
Nanobodies,31,32 and β-hairpin mimetics33. While this list continues to grow, to date, none of 
these scaffolds have come close to the success of mAbs: only a few of the core scaffolds have 





1.3 RPtag as a Novel Non-Antibody Scaffold 
 
Originally developed in 2018 by Blanden and coworkers, RPtag is a novel, non-antibody 
scaffold deriving from a ribose-binding protein native to the thermophilic Caldanaerobacter 
subterraneus. RPtag is extremely thermostable (Tm ~ 102°C), maintains its binding capacity 
over a wide pH range (pH = 4.0-10.0), is tolerant to multiple freeze-thaw cycles, can be refolded 
after treatment with common denaturants including 6M guanidinium-HCl, is resistant to GI 
proteases, is highly expressing in Escherichia coli (>1.3 g/L), and can be made into an orally 
bioavailable formulation using the B12 intrinsic factor pathway.34 Ultimately, these properties 
qualify RPtag as a potential therapeutic candidate for oral delivery which warrants further 
investigation.  
Previously, RPtag has been shown to tightly bind (KD = 47 pM) RPtag(tight): a synthetic 
19-mer peptide sequence which was designed from a series of pronounced β-sheets which lie 
on the exterior of the native ribose-binding protein (Figure 1a).34 Using PyMOL Blanden and 
coworkers identified a binding cleft comprising of 32 residues that are within 5 Å of the β-sheets 
from which RPtag(tight) was derived (Figure 1b). In addition, Blanden and coworkers illustrated 
that the RPtag binding cleft could be modified to accommodate additional targets, such as 
bioactive, dimeric PDGF-β (KD = 75 nM). The binding of RPtag to a non-native target such as 
PDGF-β warranted further investigation into the tunability of the scaffold to additional 






Figure 1. RPtag-RPtag(tight) interaction. (a) Ribbon model of the RPtag(tight) peptide bound to 
RPtag. (b) Surface model of the RPtag(tight) peptide inside the canonical RPtag binding cleft 
described by Blanden and coworkers.34 
 
In the next few sections, I discuss the development of a high-throughput fluorescence 
polarization screen allowing for rapid iteration of RPtag variants, as well as methods for the 
expression and synthesis of RPtag variants and fluorescently labeled target peptides, 
respectively. After synthesizing 33 epitope peptides from clinically or disease relevant targets, I 
conduct a preliminary screen using 28 RPtag variants originally developed by Blanden and 
coworkers (Chapter 2). I then conduct a broad, unbiased screen using Asp, Lys, Ser, and Phe 
single point mutations to the 32-AA RPtag binding cleft, and use the results to inform rational 
design of new RPtag variants with higher affinity towards targets (Chapter 3). Finally, I use SPR 
to evaluate a high-affinity anti-PD-L1 RPtag variant against recombinant extracellular PD-L1 and 
discuss results and implications of the work (Chapter 4). Experimental details, reagents, and 






1.4 Selection of Clinically Relevant Epitope Peptides 
 
 Epitopes were identified from oncogenic targets which have been or are currently 
undergoing investigation in clinical trials. The targets include: programmed cell death protein 1 
(PD-1) and its associated ligand (PD-L1), tumor necrosis factor alpha (TNF-α) and the receptor 
superfamily members 9 (CD137, TNFRSF9) and 4 (TNFRSF4, OX40) and its associated ligand 
(OX40L), and VEGF family members including VEGF-A, VEGF-B, VEGF-C, and VEGF-D, as 
well as ligand receptors VEGFR-1 and VEGFR-2. For each target, continuous linear epitopes 
were identified using the National Institute of Allergy and Infectious Disease (NIAID) immune 
epitope database and analysis resource (IEDB.org). 
 
1.5 Fluorescence Polarization/Anisotropy for Rapid Protein-Peptide Screening 
 
 1.5.1 Theory  
 
Since Weber applied the technique to characterizing ovalbumin and albumin in 1952, 
fluorescence polarization/anisotropy has become a widely used tool for evaluating protein-ligand 
interactions.35,36 Throughout the text, fluorescence polarization or FP (arbitrary units of mP) and 
fluorescence anisotropy (arbitrary units of r) are used interchangeably. It is important to note the 
only differences between the two terms are mathematical, as described by Equations 2 and 3. 
Modern versions of the technique are highly amenable to high-throughput formats by making 
use of 96-well, 384-well, and even 1536-well plate layouts. For evaluating interactions between 
proteins and small peptides, fluorescence polarization is particularly well-suited: site-specific, 
1:1 fluorophore linking is easily amenable to modern solid-phase peptide synthesis (SPPS), 
thus eliminating the need for post-production labeling of proteins or peptides, which may lack 
site specificity depending on the availability of modifiable lysines or cysteines (i.e. for NHS 
Amide or maleimide based coupling). For fluorescent labeling of peptides, the chosen 
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fluorophore needs to have a sufficiently long excited-state lifetime (e.g. fluorescence lifetime) to 
provide adequate distinction between ligand-bound and unbound states. This principle is 
illustrated by Perrin’s 1926 equation which describes how polarized light becomes depolarized 
after excitation and emission from a fluorophore having fluorescence lifetime τ:  












) (1 +  
𝑅𝑇
𝜂𝑉
𝜏)                                                                    (1) 
where p is the experimentally obtained fluorescence polarization, p0 is the fundamental 
polarization of the molecule under ideal conditions when rotational depolarization is not 
occurring (i.e. the molecule is not rotating: T/η → 0), R is the universal gas constant (8.314 J K-1 
mol-1), T is absolute temperature, η is the solution viscosity in poise, and V is the molar volume 
of the molecule.37 Weber applied Perrin’s equation to describe the change in polarization of 
macromolecules, both in terms of fluorescence polarization, p (eq. 2) and fluorescence 
anisotropy, r (eq. 3):37 
                                                        𝑝 =  
𝐼𝐼𝐼 − 𝐺𝐼ꓕ
𝐼𝐼𝐼 + 𝐺𝐼ꓕ
                                                                                               (2) 
                                                        𝑟 =  
𝐼𝐼𝐼 − 𝐺𝐼ꓕ
𝐼𝐼𝐼 + 2𝐺𝐼ꓕ
                                                                                             (3) 
where G is the instrument correction, or G factor, III and Iꓕ are the emissions of fluorescent light 
which are parallel and perpendicular to the plane of polarized light, respectively. The rotational 
correlation time (θrot) of the fluorescently tagged ligand is directly proportional to its 
hydrodynamic volume (Vh), which becomes increasingly apparent in the case of large 
biomolecules. Using the Stokes-Einstein-Debye equation38 (4) in conjunction with Perrin’s 
equation (Equation 1), these parameters can be directly related to the measured fluorescence 
anisotropy or polarization: 
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(𝑣 + ℎ)                                                                        (4) 
where kB is Boltzmann’s constant (1.38e-23 J K-1), MW is the molecular weight, v is the specific 
volume, and h is the protein hydration in g H2O per g protein. Using these equations, the 
relationship between polarization, fluorescence lifetime, and molecular weight can be 
established (Figure 2). This relationship is critical for selecting a fluorophore which is suitable for 
FP studies involving macromolecules. The fluorophore must have a sufficiently long excited-
state lifetime to allow its cargo to rotate far enough, thus allowing for a large enough 
depolarization of the emitted light which is quantifiable by the instrument. For any fluorophore, 
increasing molecular weight of the fluorophore-conjugate-protein complex approaches a 
saturable polarization limit. Thus, the binding of a fluorescently tagged 2 kDa peptide to a 28 
kDa protein produces a greater change in polarization than if the fluorophore was conjugated to 















Figure 2. Theoretical relationship between polarization and molecular weight for several 
common fluorophores. Each fluorophore is listed from top to bottom with excited-state lifetime 
(τ) values: black, Rhodamine B; magenta, FITC (fluorescein isothiocyanate); teal, BODIPY TR 
(boron dipyrromethene); purple, KU560. The dotted vertical black line represents a 2 kDa 
peptide, and the dashed vertical black line represents binding of this peptide to a 28 kDa 
protein. Simulations assume p0 = 0.5 for each fluorophore and rigid attachment of the 






 1.5.2 Evaluating RPtag Binding Using Fluorescence Polarization/Anisotropy 
 
To rapidly evaluate RPtag variant affinity towards multiple targets, proteins were titrated 
against a fixed concentration of Rhodamine B-labeled epitope peptides and evaluated using 
fluorescence anisotropy. Most of the peptides were between 2-3 kDa in size, and the canonical 
RPtag sequence has a mass of 28 kDa. For fluorophore selection, Rhodamine B has a relatively 
short excited-state lifetime (τ = 1.7 ns) compared to other dyes, but this is sufficiently long to 
observe a 2 + 28 kDa change in mass due to peptide-RPtag binding (Figure 2). Additionally, as 
the fluorophore has a higher theoretical fluorescence polarization at 30 kDa than dyes with 
longer excited-state lifetimes, the signal quantification between the polarization maxima and 
minima is larger. For these reasons, screening a large variety of peptides against RPtag 
variants was amenable to a plate-based fluorescence polarization assay (detailed plate layouts 
and methods are provided in Chapters 2 and 3). While more structurally informative, screening 
larger, recombinant 20-40 kDa protein targets would have required the use of a fluorophore with 
a significantly longer excited-state lifetime, such as the recently developed ADOTA (KU560) 
family of dyes39, as well as requiring time-consuming optimization of recombinant expressions 
and purification schemes. While screening recombinant targets would certainly be informative 
as an orthogonal confirmation of hit RPtag variants, a peptide-based approach was ultimately 
adopted to maximize throughput. 
 
 1.5.3 Specific Assay Considerations 
 
For fluorescence anisotropy, the concentration of the fluorescently labeled ligand should 
be kept as low as possible while achieving a sufficient s/n ratio. Ideally, the receptor or binding 
protein will always be at a higher concentration than the labeled ligand so that saturation of 
available free ligand is achieved. If the amount of available labeled ligand is drastically higher 
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than binding protein, binding events may not be observed due to large interference by unbound 
labeled ligands. If binding is occurring with pM concentrations of binding protein with nM 
amounts of free labeled ligand, the relatively small percentage of bound ligands may not be 
distinguishable. The general rule is thus this: the lower the expected KD of the interaction in 
question, the lower the assay concentration of labeled ligand needs to be. For the experiments 
which are later described in Chapters 2 and 3, ~5 nM ligand provided sufficient signal to detect 
nM binding events, but pM affinities may not have been detectable. Using fluorescence 
anisotropy, Blanden and coworkers reported a sub-nanomolar interaction between RPtag wild-
type and the RPtag(tight) peptide (KD = 47 pM) using the same instrument and layout that the 
experiments described herein were performed with, and used a 10 nM fixed concentration of 
labeled RPtag(tight). This suggests that even a ~1000-fold excess of free ligand does not 
interfere with measurement of substantially lower pM-like affinity. Nevertheless, an orthogonal 
confirmation using a more sensitive technique such as SPR is necessary. 
 Another relevant consideration to the experiments performed in Chapter 2 is the effect 
that rhodamine-labeled impurities can have on KD determination and sensitivity, as 
demonstrated by Figure 3. While changing the concentration of rhodamine-labeled peptide does 
not appreciably alter either KD or curve shape in Figure 3a, impurities arising from peptide 
synthesis may account for the discrepancy between the literature reported value and the 
experimental data. While easily removable using reverse-phase chromatography, residual 
fragments that are labeled and thus detectable can pose a problem for quantitative KD 
determinations by binding RPtag variants with different affinities, affecting the average 
anisotropy. When enough non-binding fragments are present, a clear reduction in signal, and 
ultimately sensitivity, can be observed, shown in Figures 3b and 3c. While Figure 3c shows 
similar affinity across the crude and pure peptides, this is not always the case, as evidenced by 
3b. Peptide synthesis impurities from hard-to-couple amino acids are difficult to predict in 
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advance, and can affect measurements to a wide degree, as shown here. Anecdotally, most of 
the peptides which were rescreened in Chapter 3 show how many of the KD determinations from 
the preliminary screen were under-reported (curve shifted to the right), with higher affinity 
towards the pure peptide. This was especially true in the case of PD-L1(189-199), which 
showed a marked improvement during the second and third combinatorial screens in 
















Figure 3. Effects of labeled peptide concentration and purity on fluorescence anisotropy. (a) Concentration and KD determination. 
Blanden and coworkers reported KD = 0.21 nM between the peptide and RPtag, represented by the vertical magenta line. RPtag was 
titrated from 10 µM to 1 pM against a fixed concentration of 1.8 nM peptide (black circles), 4.5 nM peptide (turquoise squares), 9 nM 
peptide (purple triangles), or 13.5 nM peptide (black diamonds). (b,c) Titration of wild-type RPtag versus (b) canonical RPtag(small) 
Nd2 and (c) RPtag(small) peptides. Pure peptides (black circles) were obtained from ThermoFisher Scientific (Waltham, MA), and 
crude peptides (turquoise squares) were manufactured in-house as described in the text. All axes are the same for each figure. 
Assays were performed as described in Materials and Methods, Chapter 2. Data presented are mean anisotropy ± SEM, n = 3, and 




1.6 Synthesis of Peptide Library using Fmoc-SPPS 
 
 1.6.1 History of Solid-Phase Peptide Synthesis 
 
 The use of solid-phase peptide synthesis (SPPS) for synthesizing short (i.e. ~10-20 AAs) 
peptide sequences is invaluable to modern biomedical research. Since Merrifield accelerated 
peptide synthesis by developing Boc (tert-butoxycarbonyl) protecting groups and solid-phase 
resin in the 1960’s, the technique has evolved to incorporate many applications including 
peptide library development, drug development and delivery, epitope mapping, vaccine 
development, protein expression, and many more.40,41 Although there are several variations to 
date, most peptide synthesis occurs with the use of functionalized solid-support resin, which can 
be polystyrene and/or a mixture of polyethylene glycol (PEG). Peptides are synthesized directly 
on the resin by using a series of protecting groups, both for the side chain and N terminus, for 
each amino acid. Boc-based synthesis makes use of acid-labile Boc groups to protect side 
chains and Nα carbons. Repeated treatments with trifluoroacetic acid (TFA) deprotect Boc-Nα 
carbons during peptide elongation, and differences in acid-lability of side chain Boc groups 
prevents premature deprotection. During the final cleavage step, hydrofluoric acid (HF) is used 
to simultaneously cleave all side chain protecting groups as well as the peptide from the resin.  
 
 1.6.2 Fmoc Deprotection 
 
Because of the dangers associated with HF (both to chemists and accidental acid 
hydrolysis of the peptide), Fmoc (fluorenylmethyloxycarbonyl) based synthesis is more 
common. The Fmoc strategy requires relatively milder treatment with TFA, and deprotection 
occurs orthogonally due to Fmoc’s base lability. Deprotection cycles occur with repeated 
treatments of piperidine, which ensures that neither the side chain protecting groups nor the 
resin is accidentally cleaved during the process. Additionally, liberated Fmoc groups highly 
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fluorescent, allowing reaction progress to be monitored spectrophotometrically. Figure 3 
illustrates the mechanism for Fmoc deprotection. Briefly, Fmoc-protected peptide (1) is reacted 
with piperidine to form an activated carbanion (2), which rearranges to form dibenzofulvene 
(DBF), releasing CO2 and the deprotected peptide in the process (3,4). Upon formation, DBF 














Figure 4. Fmoc deprotection scheme. R designates any series of amino acids. Note that 




 1.6.3 General Mechanism for SPPS of Epitope Peptides 
 
Figure 5 illustrates the general mechanism for Fmoc-SPPS of the Rhodamine labeled 
peptides. Fmoc-protected rink-functionalized resin (1) is deprotected under basic conditions 
(40% v/v piperidine in DMF), exposing the reactive primary amine. The first N-terminally Fmoc-
protected amino acid is coupled to the resin (2) using a double coupling scheme: 30-minute 
treatments of (i) N,N’-diisopropylcarbodiimide (DIC) and ethyl cyanohydroxyiminoacetate 
(Oxyma) and (ii) (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) and N,N’-diisopropylethylamine (DIPEA). While either DIC/Oxyma or HBTU/DIPEA can 
be used alone to achieve the coupling, the use of both reactions in tandem increases final 
peptide yields and purity.41 Elongation of the nascent peptide chain continues by additional 
deprotection and coupling cycles in the C → N direction (3). After the final N-terminal amino acid 
is coupled, a β-alanine is added to serve as a linker between the peptide and the fluorophore. A 
final deprotection cycle exposes the free N-terminus, which is reacted with sulfonyl chloride 
functionalized Rhodamine B sulfonyl chloride under basic conditions to form a stable 
sulfonamide bond (4). Note that SO2Cl Rhodamine B contains a sulfophenyl moiety instead of 
the carboxyphenyl found on regular Rhodamine B. Finally, both the resin and any side chain 
protecting groups (e.g. t-Bu, Boc, trityl, Pbf) are cleaved from the peptide under acidic 
conditions (5). The Rink-amide (AM) resin which was used for synthesis ultimately produces a 
C-terminal amide from cleavage. The cleavage cocktail is primarily comprised of trifluoroacetic 
acid (TFA), while Triisopropylsilane (TIS), 2,2’-(ethylenedioxy)diethanethiol (DODT), and H2O 
act as nucleophilic scavengers by trapping byproducts of cleavage, particularly t-Bu cations. 
Ultimately, removal of these byproducts from cleavage limits unintentional side reactions with 

















Figure 5. General mechanism for Fmoc-SPPS of rhodamine-labeled epitopes. R designates the side chain of the first coupled amino 
acid, and Rn is used thereafter. Conjugated rhodamine B (4) is shown in the open configuration as a sulfophenyl with a sulfonamide 
linkage to the peptide. 
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1.6.4 Coupling Using HBTU/DIPEA 
 
Figure 6 illustrates the mechanism for amino acid coupling using HBTU and DIPEA. The 
C-terminus of the new amino acid (1) is activated by DIPEA and attacks the iminium carbon on 
HBTU (2). The benzotriazole N-oxide forms an anionic nucleophile (-OBt) upon release (3) 
which attacks the remaining ester (4). Tetramethyl urea is removed as a byproduct from 
rearrangement of the intermediate (5), and the deprotected N-terminus attacks the activated 
benzotriazole ester (6). DIPEA salts are formed after removal of hydrogen (7), and displacement 
of the -OBt anion (8) results in the formation of the stable amide (9).  
 
1.6.5 Coupling Using DIC/Oxyma 
 
Figure 7 describes the coupling mechanism for DIC and Oxyma. The C-terminal 
carboxylic acid is first activated by DIC before attacking the electron-deficient carbodiimide (1) 
to form an activated O-acylisourea intermediate. The Oxyma hydroxylamine attacks the 
activated ester (2), displacing diisopropylurea and forming a second active ester with the Oxyma 
backbone (3). The free amine then substitutes the Oxyma leaving group, forming the final amide 
with the new amino acid (4). Like steps 6-8 in Figure 5 where -OBt is removed, Oxyma is 
displaced due to reformation of the amine intermediate. Although amino acids can be coupled 
using carbodiimides alone, racemization can become a significant problem due to the reactivity 
of the O-acylisourea. Carbonyl groups from upstream amino acids can react with the activated 
ester (2) to form an oxazolone intermediate, which can irreversibly form enantiomers after the 
addition of each amino acid. Hydroxylamines such as Oxyma overcome the problem both by 
rapidly reacting with the activated O-acylisourea, and by subsequently forming a less active 




1.6.6 SPPS for High-Throughput Fluorescence Polarization Screens 
 
For high-throughput fluorescence polarization screening, SPPS allowed for the rapid 
creation of ~50 epitope peptides, ~36 of which were screened in my initial assessments. 
Although more detailed explanations of methods are given (see Materials and Methods in 
Chapter 2), the Biotage Syro I peptide synthesizer accommodated the fully automated synthesis 
of up to 96 peptides in 1-5 µmol quantities, per synthesis. Even running at half-capacity, this 
drastically shortened the cost and time associated with screening in comparison to recombinant 
expressions. While the peptides did not undergo purification schemes, the concentration of 
labeled peptide is independent from fluorescence anisotropy, thus allowing for sufficient 
detection of binding events, but ultimately limiting quantitation. For my secondary screen 
involving D,K,S,F – RPtag variants, scaling up the synthesis and associated purification of 
selected peptides was amenable to the capabilities of the Syro I. Using a different configuration 
(see Materials and Methods, Chapter 3), up to 24 peptides could be synthesized in 300 µmol 
quantities per synthesis. This allowed for the production of sizable peptide batches that did not 
require extensive prior optimization, and still provided sufficient material to conduct the 
necessary experiments after one synthesis. Additionally, standardized purification schemes 
could be employed with the use of Isolera flash chromatography and a 384-spot plate based 























Figure 6. Mechanism for coupling using HBTU/DIPEA. Blue arrows represent the transfer of 
electron pairs. R designates the structure of the amino acid to be coupled, and R1 designates 
the rest of the peptidyl resin. B represents DIPEA, which upon protonation (7), forms a salt with 
















Figure 7. Mechanism for coupling using DIC/Oxyma. Blue arrows represent the transfer of 
electron pairs. R designates the structure of the amino acid to be coupled, and R1 designates 
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 To provide a clear proof-of-concept for evaluating chemically different RPtag variants, I 
conducted a FP-based screen to investigate binding affinities towards the peptide library. I 
synthesized rhodamine-labeled peptides using standard Fmoc-SPPS techniques, and 
recombinantly expressed RPtag variants in BL21(DE3) E. coli. I then screened the 33 peptides 
against 28 RPtag variants, qualitatively analyzed the results using MATLAB algorithms, and 
constructed a heatmap describing relative changes in binding affinities when compared to the 
wild-type RPtag. Finally, by discussing the strengths and limitations of this screen, I qualify the 




 Previously, RPtag has been shown to bind RPtag(small), a non-native peptide sequence 
which was engineered from the larger RPtag structure, with pM affinity.1 In addition to 
thermostability, pH stability, protease resistance, and oral bioavailability, RPtag is easily 
expressible in E. coli with high yields, and as a biologic, would thus have a substantially lower 
cost of production than mAb therapies expressed in mammalian culture. Where traditional mAb 
therapies require costly handling and transportation practices due to their fragility, the inherent 
robustness of an RPtag-based biologic may provide a comparative advantage in these areas. 
Similar to mAbs, the RPtag scaffold has been shown to be tolerant to mutations in the binding 
region, and consequently, may be tunable to bind therapeutic targets. For these reasons, RPtag 
may be well suited as a novel non-antibody biologic. However, the first and most significant pre-
clinical hurdle to investigating the therapeutic applications of RPtag is evaluating if the scaffold 
can be engineered to bind relevant, therapeutic targets with antibody-like affinity.  
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  To rapidly evaluate RPtag binding with clinically-relevant targets, RPtag mutants or 
variants having a single point mutation in the binding cleft were screened against rhodamine-
labeled epitope peptides belonging to targets from the VEGF, PD-1/L1, and TNF families using 
fluorescence anisotropy. In total, 33 epitope peptides were screened against 28 previously 
designed RPtag variants.1 The performance of each RPtag mutant against each target peptide 
is qualitatively ranked, dependent on the response observed from titration of the former against 
a fixed concentration of the latter. RPtag mutants which demonstrated specificity towards 
peptides, indicated by a saturating interaction which approaches an upper response ceiling at 
high concentrations, were labeled “High Binding” interactions, and were considered for further 
screening and optimization performed in Chapter 3.  
 Ultimately, the screen provides a clear proof-of-concept for rapidly evaluating the affinity 
of RPtag mutants towards peptides using fluorescence polarization (FP)/fluorescence 
anisotropy. For several reasons, improvements to the assay design are made in Chapter 3, 
based on the findings from the screening conducted here. Due to varying peptide purity, 
quantitative and robust analyses were not performed here, yet relative changes in affinity 
provided informative feedback for amino acid substitutions in the binding cleft. Additionally, the 
limited range of mutations highlighted the need for evaluating more diverse substitutions at each 
position within the binding cleft, thus providing a broader chemical survey for each RPtag-
peptide interaction. 
 
2.3 Materials and Methods 
 
 2.3.1 Fmoc SPPS of Epitope Peptides 
 
 For Fmoc-SPPS, peptides were synthesized at theoretical 3.6 µmol quantities using tip 
synthesis workflows that were pre-programmed with the Biotage Syro I synthesizer (Biotage, 
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Charlotte, NC). ~10 mg Rink Amide AM resin (100-200 mesh, 0.36 mmol/g functionalization) 
was loaded into each 250 µL tip synthesis vial, swelled in 120 µL DMF for 30 min, and 
deprotected using three successive treatments of 40% piperidine in DMF for 4 min each. 
Following the initial deprotection, resin was washed in 8 x 100 µL DMF for 30 s. Pre-activated 
double coupling with (a) DIC/Oxyma followed by (b) HBTU/DIPEA, was used for each cycle with 
4 molar equivalents of each Fmoc-[AA]. Amino acids were pre-activated with either (a) 0.36 M 
DIC in DMF, followed by 0.72 M Oxyma in DMF, or (b) 0.36 M HBTU in DMF, followed by 1.44 
M DIPEA in NMP. Ultimately, each pre-activation vial contained 0.14 M Fmoc-[AA] and either 
(a) 0.14 M DIC and 0.14 M Oxyma or (b) 0.14 M HBTU and 0.29 M DIPEA. 100 µL of either (a) 
DIC/Oxyma treated Fmoc-[AA] or (b) HBTU/DIPEA treated Fmoc-[AA] was transferred to the 
resin and reacted for 30 minutes, drained, and the resin washed with 110 µL DMF prior to the 
next deprotection step. A single β-alanine residue was added to the N-terminus of each peptide 
following coupling of the penultimate AA in the sequence. After completion of the synthesis, 
each peptidyl-resin was washed with three successive 200 µL treatments of DCM, followed by 3 
minutes under vacuum. For conjugation of the fluorophore, each peptidyl-resin was reacted with 
3 molar equivalents (10.8 µmol) Lissamine Rhodamine B sulfonyl chloride and 6 molar 
equivalents (21.6 µmol) DIPEA for 16 hours in the dark. Following conjugation, tip reactors were 
drained and rinsed 8 times with 200 µL DMF until washes were faintly pink and drained for 3 
minutes. All steps were performed at room temperature. For cleavage, the cocktail contained 
90% TFA, 5% TIS, 2.5% DODT, and 2.5% H2O. 200 µL of cleavage cocktail was added to each 
tip reactor and allowed to react for 4 hours at room temperature. After 4 h, the reactors were 
drained via a vacuum block into a 96-well deep plate, and 200 µL of cleavage cocktail was 
added to the reactors for an additional 30-minute incubation at room temperature. Using the 
vacuum block, the entire plate was drained again into the 96-well deep plate, and 2 mL Et2O 
was added to each well on the plate to precipitate peptide. The 96-well deep plate was 
centrifuged at 500 RCF (x g) for 5 minutes at 0°C using an Allegra X-22R centrifuge (Beckman 
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Coulter, Brea, CA) and the supernatant was removed using a glass pipette attached to a 
vacuum trap. The plate was then covered with a semi-permeable plate seal and lyophilized for 
48 hours. 
 
 2.3.2 Heterologous Expression of RPtag Variants 
 
For recombinant expressions of RPtag variants, BL21(DE3) E. coli were transformed 
with a pET28a(+) vector containing a 6H-RPL_[mutation] construct and grown overnight (10-16 
hours) on kanamycin selection plates at 37°C. 50 mL Luria broth (LB) starter cultures containing 
50 mg/L kanamycin were inoculated with 5 colonies and grown for 3-5 hours until turbid at 37°C. 
1L Luria broth cultures containing 50 mg/L kanamycin and antifoam were then inoculated with 
10 mL turbid starter culture, and induced with IPTG for a final concentration of 100 µM at an 
OD600 0.6-0.8. After 12-24 hours post-induction at 37°C, cells were pelleted by centrifugation at 
4200 RPM using a J6-MI centrifuge (Beckman Coulter, Brea, CA) for 30 minutes at 4°C and 
resuspended in 50 mL of 50 mM Tris pH 8.0 buffer containing 300 mM NaCl, 10 mM β-ME, and 
20 mM imidazole (resuspension buffer). Cell pellets were chemically lysed using 2 mg/L 
Lysozyme, 5 mg/L DNase I with 5 mM MgSO4 for 1-1.5 hours at 2-8°C. Lysate was then 
centrifuged for 1 hour, 4200 RPM, 4°C, and the supernatant was stored at 2-8°C for purification. 
A Kontes 25 x 200 mm column with 40 mL Ni-NTA resin was equilibrated with at least 10 resin-
bed volumes (RBVs) of 0.22 µm filtered de-ionized (DI) H2O to remove ethanol, and then at 
least 5 RBVs of resuspension buffer. After equilibration, lysate was added to the column and 
washed with 5-10 RBVs of the resuspension buffer. Sample was eluted using at least 5 RBVs of 
an elution buffer containing 50 mM Tris at pH 8.0, 300 mM NaCl, 10 mM β-ME and 500 mM 
imidazole. 5 mL fractions were collected and analyzed via SDS-PAGE. RPtag containing 
fractions were pooled into 10 kDa MWCO dialysis tubing and dialyzed for 12-18 hours at 2-8°C 
into 4L of dialysis buffer containing 50 mM Tris pH 8.0, 150 mM NaCl with 10 mM β-ME. 
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Dialyzed protein was analyzed via SDS-PAGE, and concentration was determined via A280 
(Beer’s law) prior to flash freezing of 1 mL aliquots in liquid N2 and storage at -80°C.  
 
 2.3.3 Fluorescence Anisotropy Assays 
 
For fluorescence anisotropy assays, 200 µL of 200 µM RPtag variant was added to each 
well on the first column of one of two adjacent black 96-well dilution plates, and 100 µL of 50 
mM Tris pH 8.0, 0.005% (v/v) Tween 20 running buffer was added to wells A2-H24 over the two 
plates. RPtag variants were diluted down the two plates by transferring 100 µL from each well to 
the next, for a total of 24, 2-fold dilutions which range from 100 µM – 12 pM (Figure 1). 
Following dilutions, 100 µL of the appropriate ~10 nM labeled peptide in the running buffer was 
added to each well on each set of plates, and fluorescence anisotropy was measured on the 
plates after 1 h incubation at room temperature in the dark assuming an instrument correction 
factor (G) of 2.7 for rhodamine (Chapter 1, Equation 3). All fluorescence anisotropy 
measurements were taken using a SpectraMax i3x (Molecular Devices, San Jose, CA).  
Peptides were not purified after cleavage, and as such, accurate concentrations of the 
desired products could not be distinguished from a bulk concentration method which would be 
influenced by truncations and/or undesired fragments (i.e. BCA/Bradford assays), and the use 
of analytical HPLC or MALDI would significantly limit throughput while still requiring sizable 
amounts of the pure material. To overcome this, lyophilized peptide was resuspended in DMF to 
create a ~10 µM substock solution assuming a universal 50% synthesis efficiency (3.6 µmol * 
0.50 = 1.8 µmol desired product) and diluted to a ~10 nM cocktail in running buffer. 100 µL of 
each cocktail was added to 100 µL buffer on a blank 96-well plate, and the anisotropy was 
compared relative to 200 µL buffer blanks. Relative fluorescence units (RFUs) were compared 
between parallel (||) and perpendicular (ꓕ) intensities between the cocktail and buffer wells, and 
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N,N-dimethylformamide (DMF), N,N’-diisopropylethylamine (DIPEA), 1-methyl-2-
pyrrolidinone (NMP), trifluoroacetic acid (TFA), triisopropylsilane (TIS), and 2,2’-
(ethylenedioxy)diethanethiol (DODT) were purchased from Sigma-Aldrich (St. Louis, MO). 
Piperidine, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 
N,N’-diisopropylcarbodiimide (DIC), ethyl cyanohydroxyiminoacetate (Oxyma), and the following 
Fmoc-protected amino acids were purchased from Chem-Impex (Wood Dale, IL): Fmoc-L-
alanine, Fmoc-L-glutamate(OtBu) hydrate, Fmoc-glycine, Fmoc-L-isoleucine, Fmoc-L-
lysine(Boc), Fmoc-L-leucine, Fmoc-L-asparagine(Trt), Fmoc-L-proline, Fmoc-L-glutamine(Trt), 
Fmoc-L-arginine(Pbf), Fmoc-L-serine(OtBu), Fmoc-L-threonine(OtBu), Fmoc-L-tryptophan(Boc), 
Fmoc-L-tyrosine(tBu). Note the side chains indicated by parentheses: (OtBu) tert-butyl ester, 
(Boc) tert-butyloxycarbonyl, (Trt) triphenylmethyl/trityl, (Pbf) 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl, (tBu) tert-butyl. Lissamine Rhodamine B Sulfonyl 
Chloride and chemically-competent BL21(DE3) E. coli cells were purchased from Thermo-
Fisher Scientific (Waltham, MA). Rink amide AM resin was purchased from Novabiochem 
(Burlington, MA). Isopropyl-β-d-1-thiogalactopyranoside (IPTG) was purchased from Gold 
Biotechnology (St. Louis, MO). All expression plasmids were synthesized, codon optimized, and 
sequence verified by GenScript (Piscataway, NJ). Black untreated 96-well polystyrene 
microplates were purchased from Corning (Corning, NY). All other reagents and materials were 



















Figure 1. Plating scheme for high-throughput fluorescence anisotropy assays. RPtag variants, 
all starting at 200 µM, were diluted down two 96-well plates to give 24 total two-fold dilutions. 
Note that after an equal volume of cocktail containing fluorescently-labeled peptide is added, the 




2.4 Development of MATLAB Algorithms and Affinity Interpretations 
 
 Several MATLAB scripts were written to handle reformatting and analysis of raw data as 
it was exported from the SpectraMax i3x. For each position in the RPtag binding cleft that was 
modified, anisotropy data for each variation was plotted per each peptide target (Figure 2). Data 
was fitted to a four-parameter logistic regression (Eq. 1): 






𝑏                                                                            (1)  
whereas a represents the baseline response (x → 0), d represents the theoretical maximal 
response when the ligand is saturated (x → ∞), b represents the slope at the inflection point of 
the curve, and c represents the concentration at which the response is half-maximal or the 
inflection point. In the case of 1:1 binding, c is the equilibrium dissociation constant, KD, as per 
the mathematically equivalent Hill-Langmuir equation2. To account for differences in peptide 
purity, calculated KD values for this screen were only interpreted relative to wild-type RPtag for 






















Figure 2. Measured binding activity between RPtag wild-type (black), RPtag-A253R (blue), 
RPtag-A253K (green), RPtag-H122L/A253R (red), and rhodamine labeled VEGFR-1(229-251) 
peptide using fluorescence anisotropy as described in the text. Each RPtag variant was serially 
diluted in a 2-fold 24-point series, n = 1. Data was fit to a four-parameter logistic regression 








2.5 Qualitative Analysis of Binding Interactions 
 
 For each peptide target, each 24-point titration was qualitatively binned into one of three 
categories: “High Binding”, “Low Binding”, or “No Binding”. To mitigate the effects of impurities 
from peptide synthesis, these rankings were assigned based on curve shape, rather than the 
mathematically approximated KD (Figure 3). Additionally, KD values could not be calculated for 
each series when ligand saturation does not occur, the binding is non-specific or 
superstoichiometric, and/or there are insufficient data points to accurately approximate an upper 
curve asymptote. RPtag variants that were marked as “High Binding” for any target 
demonstrated a sigmoidal dose-response (when presented on an x-axis logscale plot), with 
several data points approaching an upper asymptote at high concentrations. An upper saturable 
limit suggests that all available ligand is bound, and that non-specific interactions are not 
occurring. “Low Binding” described RPtag variants that exhibited a clear, sometimes linear 
increase in anisotropy at higher concentrations (generally low µM) but did not approach a 
saturable limit. “Low Binding” can indicate one of several scenarios: either the ligand binds the 
RPtag non-specifically, as evidenced by a clear lack of saturation at high concentration, or the 
interaction occurs with such low affinity that higher concentrations of RPtag would be required to 
observe saturation. Finally, “No Binding” was used to described curves that exhibited little to no 
dose-dependent response, but sometimes having slight increases in anisotropy (0.02-0.04) only 
at the highest concentrations. “Low Binding” was distinguished from “No Binding” by generally 



















Figure 3. Representative curves for qualitative evaluation of RPtag screen. Wild-type RPtag 
(black, “High Binding”), RPtag-G130A (blue, “Low Binding”), and RPtag-G130V (green, “No 
Binding”) were titrated against rhodamine-labeled VEGFR-1(229-251) peptide and fluorescence 











A summary of the preliminary screen is presented in Figure 4. As expected, RPtag had 
little measurable activity versus most of the targets including epitopes from PD-1, the TNF 
family, and VEGFR-2. RPtag demonstrated some specificity towards VEGFR-1(161-169), PD-
L1(189-199), and PD-L1(126-134), with the highest apparent affinity towards VEGFR-1(229-
251), OX40L(160-178), and VEGF-C(225-233). This screen shows the tunability of the RPtag 
scaffold towards several targets and provides evidence that the canonical binding cleft is the 
source of most interactions. Although the rationalizations of each observed change in affinity 
cannot and should not be fully explained at this point, these observations form the basis for 
further screening, including the rational mutagenesis in Chapter 3. Thus, several examples and 
possible rationalizations will be given to demonstrate both points.  
 
2.6.2 RPtag Specifically Binds VEGFR-1(229-251), VEGF-C(225-233), and OX40L(160-178) 
 
 RPtag-A253K demonstrated a marked improvement in affinity towards VEGFR-1(229-
251) whereas A253R had no effect (Figure 2). This could be a due to a relatively higher steric 
hinderance of the guanidinium in comparison, and its inability to reach a negatively charged 
residue on the peptide. For VEGF-C(225-233), RPtag-M270E demonstrates a similar 
improvement compared to M270N, M270R, and M270K (Figure 5), possibly forming a salt 
bridge with a positively charged Lys or Arg. Interestingly, M270N had a lesser but noticeable 
effect, which may be due to relatively weaker hydrogen bonding with the positive residue. 
Mutations which decrease affinity are valuable as well: RPtag-G130V has almost no 
measurable affinity towards VEGFR-1(229-251), likely indicating that G130 is a key residue for 
binding (Figure 3). The most straightforward explanation is the effect of steric hinderance that a 
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valine has on the ability of the peptide to fit into the binding cleft, although hydrophobicity could 
play a part as well. Finally, mutations which do not affect affinity may also have value. Modifying 
residues which do not affect affinity can potentially eliminate unwanted binding by altering 
specificity. For a hypothetical RPtag VEGFR-1 drug that binds the 229-251 region, D126F may 
be preferable than D126L, for example. While both D126L and D126F have similar affinity 
towards VEGFR-1(229-251), D126F had almost no affinity towards VEGFR-1(172-189), 
whereas D126F retained some binding capacity which was likely non-specific (Figure 4). Many 
RPtag mutants improved binding to OX40L(160-178) and demonstrate increased specificity 
towards the target. K129Y, for example, appears to reach saturation at the 10-100 µM range, 
which is not demonstrated by the wild-type or other mutations at this position (Figure 6). This 
may be due to preference of a pi-stacking interaction with nearby Phe, Trp, or Tyr residues on 
the OX40L(160-178) peptide, or hydrogen bond exchange with a hydrophilic residue.  
While comprehensive, the fluorescence anisotropy experiments described in this chapter 
demonstrate the need for quantitative KD determination and broader, unbiased mutational 
survey of the RPtag binding cleft. The possibility of contaminants from the peptides raises two 
issues: the inability to reliably determine KD values, and decreased sensitivity. The presence of  
fluorescently labeled impurities that do not bind with the same affinity as the full-length peptide 
can cause an underreported (i.e. higher) KD value. Additionally, when RPtag binds full length 
peptide, labeled impurities which bind with relatively less affinity will decrease the average 
anisotropy of the solution, causing a bulk reduction in assay sensitivity. Conversely, labeled 
impurities that bind with higher affinity than the RPtag could cause the apparent affinity to 
increase, leading to false positives. Finally, the RPtag variants designed by Blanden and 
coworkers were selected for optimizing an interaction with one particular target. While useful as 
a proof-of-concept, the mutants do not span every position on the RPtag binding cleft, nor do 
they survey every category of protein-protein/protein-peptide interaction. For example, Ala and 
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Val substitutions were made at G130 which may represent hydrophobic branched chain 
interactions, but salt bridge formation (Asp/Glu or Lys/Arg substitution), hydrogen bonding 
(Ser/Thr, among others), or aromatic pi stacking (Phe/Trp/Tyr substitution) were not evaluated. 
This consideration was applied to the following round of screening, which aimed to broaden the 

































Figure 4. Heatmap summarizing fluorescence anisotropy assays between 28 RPtag variants 
and 33 clinically relevant epitope peptides. Each square represents one 24-point titration 
between an RPtag variant, below, and each target peptide, left, measured by fluorescence 
anisotropy. Asterisks denote the best performing peptides mentioned in the text; OX40L(160-
















Figure 5. Measured binding activity between RPtag wild-type (black, “No Binding”), RPtag-
M270N (blue, “Low Binding”), RPtag-M270R (green, “Low Binding”), RPtag-M270E (red, “High 




















Figure 6. Measured binding activity between RPtag wild-type (black, “Low Binding”), RPtag-
K129Y (blue, “High Binding”), RPtag-K129A (green, “Low Binding”), RPtag-K129H (red, “Low 










2.7 Conclusions  
 
 RPtag demonstrated tunability and specificity towards several targets, including PD-L1, 
VEGFR-1 and VEGF-C, and OX40L. Several mutants had a qualitatively significant change in 
curve shape, at times showing a saturable limit and thus indicating specific binding. Quantitative 
changes in binding affinity could not be reliably calculated due to lack of knowledge concerning 
the extent to which impurities affected binding. Additionally, the scope of the RPtag mutants 
covered only a small range of interactions, and substitutions did not occur at several binding 
cleft residues.  
To address these issues, a broad survey screen was conducted in Chapter 3 which uses 
119 RPtag single-point mutants containing an Asp, Lys, Ser, or Phe at each binding cleft 
residue. To quantitatively measure binding activity, 24 rhodamine labeled peptides were 
resynthesized at a larger scale and purified using Isolera flash chromatography, analytical 
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 To further understand binding interactions centered at the RPtag binding cleft, a limited, 
site-directed mutagenesis was carried out to improve affinity towards epitopes of interest. To 
survey a wide variety of chemical changes at the RPtag binding cleft which could ultimately 
promote protein-protein interactions, each canonical position was substituted for each of four 
amino acids, which represented the most common non-covalent attractions that improve 
binding. As a follow-up, RPtag mutants which held the highest affinity towards peptide targets of 
interest were rescreened, and the best mutants were combined to create rationally-engineered 
mutants with high affinity towards two high-priority targets: PD-L1 and VEGFR-1. Finally, the 





 In chapter 2 I conducted a preliminary fluorescence anisotropy screen of 28 RPtag 
variants with single point mutations and probed for binding affinity against 33 clinically relevant 
epitope peptides from the VEGF, TNF, and PD-1 families. Several RPtag mutants demonstrated 
increased affinity towards several targets, with respect to the wild-type RPtag. In particular, the 
following targets demonstrated a qualitative “High-Binding” ranking (see chapter 2, Figure 10) 
towards at least one RPtag variant: OX40L(160-178), PD-L1(126-134), PD-L1(189-199), VEGF-
C(225-233), VEGFR-1(161-169), and VEGFR-1(229-251). Ultimately, this demonstrated the 
tunability of the RPtag scaffold towards different peptide targets and provided evidence that 
binding with these targets was centered at or near the RPtag binding cleft.  
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 While the preliminary screen provided a clear proof-of-concept for engineering RPtag to 
bind non-native targets, there were two issues which limited the resolution and scope of the 
experiments. Firstly, uncharacterized impurities in the peptides prevented quantitative analyses 
and decreased assay sensitivity. The reasons for this are thoroughly explained in chapter 2, but 
ultimately, post-synthesis purification schemes of the manufactured peptides would be needed 
to overcome these issues. The purification process must include a characterization step which 
confirms the presence of the full-length peptide, as well as fluorescently labeled and unlabeled 
impurities. Secondly, the small number of random mutants that were screened surveyed only a 
small window of protein-peptide interactions. Out of the 32 residues that make up the canonical 
RPtag binding cleft, single-point mutations were only substituted at 9 of these positions, and 
many of the mutations did not cover each “category” of protein binding interactions (see Section 
2.7).  
 Therefore, the purpose of this study was to conduct a robust analysis of RPtag-peptide 
binding by mutating each of the canonical 32 binding cleft residues into each of four key 
residues: Asp (D), Lys (K), Ser (S), or Phe (F). These amino acid substitutions were chosen to 
generate a library of single-mutant RPtag variants to pinpoint beneficial or detrimental effects 
that each substitution could have on affinity (i.e. KD). The reasons for why these four amino acid 
substitutions were selected are as follows: Asp (D) and Lys (K) as anionic and cationic residues 
that promote formation of salt bridges,1,2 Ser (S) to increase hydrophilicity by means of 
hydrogen bond donation and acceptance,3,4 and Phe (F) to increase hydrophobicity and engage 
in pi-pi stacking interactions with aromatic residues.4–7 As most protein-protein interactions rely 
on combinations of these non-covalent attractions, D, K, S, and F RPtag mutants alone could 
broadly determine if any of these interactions affect binding. While not accounting for the effects 
of subtle structural differences between chemically similar residues (e.g.: Glu and Asp), this 
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approach allows for rapid optimization of the RPtag binding cleft towards each target by means 
of identifying and substituting key amino acids. 
To address issues arising from varying peptide purities, 24 peptides from the preliminary 
screen were resynthesized, purified, and characterized for impurities. The D, K, S, and F RPtag 
variants (117 in total) were screened against the 24 purified peptides using fluorescence 
anisotropy, and the results were characterized with respect to each peptide target. To confirm 
“hits”, selected targets were rescreened against several RPtag mutants before ‘combinatorial’ 
mutants were designed, against VEGFR-1(229-251) and PD-L1(189-199), which contained 2-4 
high-affinity D,K,S, and/or F point mutations. Ultimately, the affinity of RPtag towards both 
VEGFR-1(229-251) and PD-L1(189-199) was substantially increased as a result of these 
efforts, indicating that RPtag tightly binds both of these targets in a specific manner 
 
3.3 Materials and Methods 
 
 3.3.1 Fmoc-SPPS of Selected Peptides 
 
 For re-synthesis of the selected peptides, 278 mg of Rink Amide AM resin (100-200 
mesh, 0.36 mmol/g functionalization) was loaded into each 10 mL reactor, corresponding to a 
theoretical 100 µmol synthesis scale. Each resin aliquot was swelled with 2 mL DMF for 30 
minutes prior to the first deprotection step. For deprotection, each aliquot was treated with 2.4 
mL 40% piperidine in DMF for 15 minutes and vortexed every minute for 10 seconds. Each 
aliquot was washed with six successive treatments of 1.8 mL DMF after deprotection, with an 
initial 10 second vortex period followed by 50 seconds at rest and a 30 second drainage. For 
coupling, 4 molar equivalents of each respective Fmoc-[AA] was added to each vial, followed by 
treatment with (a) DIC/Oxyma or (b) HBTU/DIPEA using the same concentrations as previously 
described in Section 2.3.1. Each coupling cycle lasted 45 minutes with a 15 second vortex every 
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2 minutes. After each coupling cycle, the reactors were washed once with 2.1 mL DMF and 
drained. An additional β-alanine residue was coupled to the N-terminus of each peptide after the 
sequence was finished.  
Following synthesis, resins were washed with three successive 2 mL treatments of 
DCM, followed by 3 minutes under vacuum. Rhodamine conjugation occurred as previously 
described, followed by 8 successive washes with 2 mL DMF, at which point the washes were 
faintly pink, followed by vacuum for 3 minutes. The same cleavage cocktail was created as 
described previously in Section 2.3.1, and each 10 mL peptidyl-resin reactor was treated with 2 
mL cocktail, sealed, and placed on a rocking platform for 4 h incubation at room temperature. 
After incubation, each reactor vial was plunged into 50 mL conical tubes and treated with an 
additional 2 mL aliquot of cocktail for 30 minutes, resealed, and allowed to sit on the rocking 
platform. Following incubation, the collected cleavage fractions were pooled into the same 50 
mL conical tubes, and the solid 10 mL reactor vials were discarded. Cleavage aliquots were 
treated with ~40 mL cold (-80°C) Et2O, allowed to sit for 5 minutes at room temperature, and 
centrifuged at 300 RCF for 30 minutes at 0°C. The supernatant was decanted as waste, and the 
remaining peptide pellet was treated with a second ~40 mL aliquot of cold ether, incubated at 
room temperature, and centrifuged as described. Following the last decanting, the remaining 50 
mL tubes containing solid peptide were flash frozen in liquid N2 and lyophilized for 48-72 h 
before storage at -80°C. 
 
 3.3.2 Isolera Purification of Rhodamine-Labeled Peptides 
 
 For peptide purification using the Isolera Flash Chromatography System, 0.5-1.0% (w/w) 
crude peptide (125-250 mg) was solubilized in 1 mL of either DMSO or DMF (the latter if the 
peptide contained Cys or Met residues) and loaded onto a 25 g Biotage SNAP Bio C18 (20 µm, 
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300 Å, 33 mL CV) column. Peptides were eluted using a gradient of 10-100% MeCN in H2O 
over 20 CV at the manufacturers recommended flow rate of 40 mL min-1. 1% (v/v) TFA or 
NH4OH (the latter if the peptide pI < 6) was mixed at a percentage of 10% with neat H2O for a 
final concentration of 0.1% (v/v) during the gradient. The collection threshold was 50 mAU for λ 
= 200-400 nm, with monitoring at λ = 215 nm and 355 nm (rhodamine). Rhodamine labeled 
fractions were pooled and MeCN was removed via rotary evaporator for 20-30 minutes prior to 
flash freezing in liquid N2 and lyophilization for 48-72 hours.  
 
 3.3.3. Analytical HPLC and MALDI-ToF-MS of Peptides 
 
 For analytical HPLC of the purified peptides, 20 µL of 10-100 µg of each peptide in 
DMSO or DMF (the latter if the peptide contained Cys or Met residues) was injected onto a 
Waters XBridge Peptide BEH C18 column (5 µm, 300 Å, 4.6 mm x 150 mm). A gradient of 10-
50% MeCN + 0.1% (v/v) TFA in H2O + 0.1% (v/v) TFA was applied over 40 minutes at a flow 
rate of 1 mL min-1 at 20°C using a Waters 2695 separations module. Sample detection occurred 
at 215 nm, 280 nm, 355 nm, and 560 nm using a Waters 2996 photodiode array detector (PDA). 
Sample purity was determined by baseline integration using Waters Empower 3 software. For 
MALDI-ToF-MS of the purified peptides, 1 µL of 0.5-1.0 mg/mL peptide in H2O was mixed with 9 
µL spotting matrix: 10 mg/mL α-cyano-4-hydroxycinnamic acid (CHCA) in 50:50 MeCN/0.1% 
(v/v) TFA in H2O. 2 µL of each peptide spotting solution was spotted onto a Bruker MTP 384 
Target Plate and allowed to dry at room temperature for at least 30 minutes prior to analysis. 
Samples were analyzed on a Bruker Autoflex iii Mass Spectrometer, using 15% laser power 
with an m/z range from 1000-5000 Da with suppression <400 Da in linear mode with 35x 




3.3.4. Recombinant Expressions of RPtag Mutants and Fluorescence Polarization Assays 
 
 All recombinant expressions were performed as described in Section 2.3.2. 
Fluorescence anisotropy assays were performed as described in Section 2.3.3, with the sole 
exception that RPtag-[Mutant] constructs were diluted in 2-fold, 24-point titrations starting from 
10 µM, instead of 100 µM. As previously described, RFU intensities from the 10 nM peptide 
cocktails were determined to ensure parallel and perpendicular intensities were > 10 times the 




Acetonitrile (MeCN), diethyl ether (Et2O), dimethyl sulfoxide (DMSO), N,N-
dimethylformamide (DMF), N,N’-diisopropylethylamine (DIPEA), 1-methyl-2-pyrrolidinone 
(NMP), trifluoroacetic acid (TFA), triisopropylsilane (TIS), and 2,2’-(ethylenedioxy)diethanethiol 
(DODT) were purchased from Sigma-Aldrich (St. Louis, MO). Piperidine, (2-(1H-benzotriazol-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), N,N’-diisopropylcarbodiimide 
(DIC), ethyl cyanohydroxyiminoacetate (Oxyma), and the following Fmoc-protected amino acids 
were purchased from Chem-Impex (Wood Dale, IL): Fmoc-L-alanine, Fmoc-L-glutamate(OtBu) 
hydrate, Fmoc-glycine, Fmoc-L-isoleucine, Fmoc-L-lysine(Boc), Fmoc-L-leucine, Fmoc-L-
asparagine(Trt), Fmoc-L-proline, Fmoc-L-glutamine(Trt), Fmoc-L-arginine(Pbf), Fmoc-L-
serine(OtBu), Fmoc-L-threonine(OtBu), Fmoc-L-tryptophan(Boc), Fmoc-L-tyrosine(tBu). Note 
the side chains indicated by parentheses: (OtBu) tert-butyl ester, (Boc) tert-butyloxycarbonyl, 
(Trt) triphenylmethyl/trityl, (Pbf) 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, (tBu) tert-
butyl. Lissamine Rhodamine B Sulfonyl Chloride and chemically-competent BL21(DE3) E. coli 
cells were purchased from Thermo-Fisher Scientific (Waltham, MA). Rink amide AM resin was 
purchased from Novabiochem (Burlington, MA). Isopropyl-β-d-1-thiogalactopyranoside (IPTG) 
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was purchased from Gold Biotechnology (St. Louis, MO). All expression plasmids were 
synthesized, codon optimized, and sequence verified by GenScript (Piscataway, NJ). Black 
untreated 96-well polystyrene microplates were purchased from Corning (Corning, NY). The 
Isolera Flash Chromatography System and Biotage SNAP Bio columns were purchased from 
Biotage AB (Uppsala, Sweden). HPLC was performed using Waters XBridge columns and a 
Waters 2695 Separations Module with 2996 Photodiode Array (Milford, MA). MALDI-ToF was 
conducted using a Bruker Autoflex iii Mass Spectrometer (Billerca, MA). All other reagents and 
materials were purchased from Millipore Sigma (Burlington, MA).  
 
3.4 Limited Site-Directed Mutagenesis of RPtag  
 
  To evaluate RPtag mutant binding to each peptide target, dose-response curves were 
first analyzed qualitatively as described in Section 2.5. Sigmoidal responses approaching 
saturation, having several points between the upper and low limits and a large change in 
anisotropy (~0.15) were considered indicative of specific binding events. Showing some overlap 
from the preliminary screen, titrations of RPtag displayed an ideal, saturable dose-response 
profile towards PD-L1(189-199) and VEGFR-1(229-251). PD-L1(126-134), OX40L(160-178), 
and OX40L(111-119) displayed some activity against the wild-type RPtag, but the anisotropy did 
not fully saturate at high concentrations. Many other peptides displayed a linear increase in 
anisotropy at high concentrations of RPtag but did not approach any saturable limit, such as 
RPtag-G130A against VEGFR-1(229-251) in Chapter 2, Figure 3. For these reasons as well as 
their clinical relevance (see chapter 4, PD-L1 as an Immunomodulatory Drug Target), PD-
L1(189-199), as well as VEGFR-1(229-251) were slated for further analysis through rational 
design of RPtag mutants by combining the best performing single point mutations. PD-L1(126-


















Figure 1a. Summary of D,K,S,F RPtag mutants. Each canonical residue in the RPtag binding 
cleft (1b) was substituted for a Ser, Asp, Lys, or Phe, where applicable (1a). The following 
mutants had low expression yields and were omitted from screening: RPtag-K129S and RPtag-
D126F. Each RPtag mutant was expressed in E. coli with an N-terminal 6xHis tag and purified 



















Figure 1b. Ball and stick representation of the RPtag binding cleft. Each of the canonical 32 residues, labeled at each side chain, are 















Figure 2. Selected RPtag mutants with affinity towards OX40L(160-178) (a) and OX40L(111-119) (b). Black lines represent wild-type 
RPtag for each plot, for which data shown is mean anisotropy ± SEM, n = 3. All mutants were screened in single replicate. All data 













Figure 3. RPtag mutants increase binding to PD-L1(126-134). Black lines represent wild-type RPtag for each plot, for which data 
shown is mean anisotropy ± SEM, n = 3. All mutants were screened in single replicate. All data was fit using a 4PL regression in 

















Figure 4. RPtag mutants increase binding to PD-L1(189-199) (a-c) and VEGFR-1(229-251) (d-f). Black lines represent wild-type 
RPtag for each plot, for which data shown is mean anisotropy ± SEM, n = 3. Where applicable, KD values are mentioned in the text. 
All mutants were screened in single replicate. All data was fit using a 4PL regression in MATLAB, as described in chapter 2. 
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3.5 Results from Fluorescence Polarization Assays 
 
3.5.1 Tunability of RPtag towards OX40L(160-178) and OX40L(111-119) 
 
 Wild-type RPtag demonstrated some affinity towards OX40L(160-178) and OX40L(111-
119) as shown in Figure 2a and 2b, respectively. KD determination could not be reliably 
quantified due to lack of sigmoidal curve shape for titration of wild-type RPtag. However, several 
mutants exhibited sigmoidal binding responses towards these targets, suggesting binding that is 
non-superstoichiometric and specific. For OX40L(160-178), RPtag-D126K provided the largest 
change in affinity when compared to other mutants (not shown), with a KD = 126.4 nM. For 
OX40L(111-119), RPtag-A257K provided the largest change out of the screen with a KD = 235.5 
nM. For both OX40L epitopes, a marked improvement in binding affinity was observed due to 
the substitution of Lys residues. Further evaluations of RPtag binding to OX40L(160-178) and 
OX40L(111-119) could include substitution of Arg at these positions, and/or inclusion of Lys/Arg 
at nearby positions in the binding cleft. Regardless, both RPtag mutants show an apparent 
specificity towards the target ligands, opening the possibility for further tuning of the scaffold 
towards either epitope. However, the close positioning of these epitopes on OX40L highlights 
the importance of minimizing off-target interactions when considering rational amino acid 
substitutions. Ultimately, an epitope target would need to be selected which, when bound, 
produces the desired effect in vivo (i.e. disruption of OX40 binding OX40L). RPtag maintaining 
affinity may not be desirable towards both epitopes, in which case mutants which only lower 
affinity towards the undesired epitope, while having little to no effect on the alternative would 
need to be engineered. This is further explained in chapter 4 when discussing strategies for 





 3.5.2 PD-L1(126-134) as a Priority Epitope For PD-1/L1 Inhibition 
 
 The RPtag mutant library demonstrated less affinity to PD-L1(126-134) compared to its 
upstream counterpart, PD-L1(189-199). However, the increase in affinity which three RPtag 
mutants have towards the epitope demonstrates how targeting PD-L1(126-134), demonstrated 
by Figure 3, may be a preferable alternative to PD-L1(189-199). Natively, in vivo N-
acetylglucosamine (GlcNAc) glycosylations at Asn 192 and Asn 200 could prohibit RPtag from 
effectively targeting the Lys 189 – Ile 199 motif. In addition, several residues which are nearby 
to or reside within the Ile 126 – Tyr 134 motif have been shown to be responsible for much of 
the ligand’s interactions with PD-1, and are also critical to interacting with the clinical PD-L1 
inhibitors Avelumab and Atezolizumab.8,9 On this basis alone, PD-L1(126-134) lends itself to 
being a high priority epitope in the context of drug discovery.  
Figure 3 demonstrates several RPtag mutants which increase affinity towards PD-
L1(126-134). RPtag-K129F (Fig. 3a), RPtag-F137S (Fig. 3b), and RPtag-G130K (Fig. 3c) 
display an increased affinity with respect to the wild-type, albeit none of these RPtag mutants 
reach saturation at high concentrations. It is worth noting that RPtag-G130K (Fig. 3c) appears to 
saturate at 1-10 µM with an apparent KD in the 100-1000 nM range, but lack of additional 
replicates limits reliable quantitation. The apparent lack of saturation or specificity implies that 
individually, the effects of substituting these residues (i.e. K129F, F137S, and G130K) is not 
great enough to provide ligand saturation at the highest concentrations tested in this assay. All 
three mutants promote different non-covalent interactions at their respective positions, despite 
having proximity to one another. For each respective position, K129F increases hydrophobicity, 
F137S increases hydrophilicity, and G130K creates a cationic charge. Combined with the low 
affinity of the wild-type to the epitope, this could indicate that different mutants are resulting in 
different positionings of the peptide in the binding cleft.10 This appears unlikely, however, as the 
anisotropy changes observed in Fig. 3a-c are occurring at concentrations well below even the 
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weakest specific protein-protein interactions.11 Mutations which perform worse than the wild-
type at these positions could indicate a specific interaction as well, if the right-ward changes in 
anisotropy (i.e. at higher concentrations) are not artefacts of assay noise. If a hydrophobic 
interaction is preferred at Lys 129 (Fig. 3a), one would expect a Phe to increase affinity 
compared to ionic interactions such as from an Asp or the wild-type. Figure 3c also represents a 
clear increase in affinity arising from the G130K mutation. At Gly 130, a positively-charged Lys 
(Fig. 3c, green line) is preferred to an Asp (Fig. 3c, red line), which kills all measurable activity. 
This may be due to the donation of a hydrogen bond by Lys to an acceptor on the peptide, 
whereas Asp is unable to act as a hydrogen bond donor at a neutral pH. Figure 3b shows an 
additional example, where a non-ionic hydrophilic Ser replacing at Phe 137 increases affinity of 
RPtag towards PD-L1(126-134) more than either a Lys or Asp at the same position. While none 
of the RPtag mutants perform as well towards PD-L1(126-134) as they do PD-L1(189-199) (Fig. 
4a-c) or VEGFR-1(229-251) (Fig. 4d-f), the importance of the epitope location for PD-1 binding, 
as well as nearby interactions with clinically-approved inhibitors warrants further optimization of 
RPtag mutants towards this target.  
 
3.5.3 RPtag Binds VEGFR-1(229-251) and PD-L1(189-199) with High Affinity 
 
 Among the 24 epitopes, wild-type RPtag displayed the highest affinity towards VEGFR-
1(229-251) and PD-L1(189-199), with calculated KD values of 179.5 nM and 103.6 nM, 
respectively (no replicates, Table 1). For both peptides, RPtag mutants which substantially 
increased affinity are shown in Figure 4. For PD-L1(189-199), RPtag-L275D (Fig. 4a) and 
RPtag-M270F (Fig. 4c) increased affinity by approximately an order of magnitude, with KD 
values of 41.94 nM and 37.98 nM respectively. Several mutants, including RPtag-A254F (Fig. 
4b) removed all measurable affinity towards the peptide, suggesting the presence of residues 
which are critical to ligand binding. Here, Ala 254 appears to be preferential to Asp, Lys, and 
58 
 
Phe, which may indicate that the flexibility and chemical inertness of the methyl side-chain is 
allowing for a better fit of the peptide, improving interactions with nearby residues within the 
binding cleft. To evaluate this, one possible mutant could be A254G, which could promote 
flexibility and decrease steric hinderance within the binding cleft. For VEGFR-1(229-251), 
RPtag-A257F (Fig. 4d) and RPtag-I247F (Fig. 4e) appreciably improved binding from the wild-
type, with KD values of 40.05 nM and 19.10 nM, respectively. Being proximal to each other (see 
Fig. 1b), the two Phe substitutions may be affecting the same hydrophobic residue(s) on the 
VEGFR-1(229-251) peptide. Interestingly, RPtag-I256F did not have a beneficial effect on 
affinity, despite being close to both Ala 257 and Ile 247 (Fig. 4f), indicating that this position is 
likely not close enough to the same hydrophobic region being targeted by the latter two residues 



























Table 1. Summary of wild-type RPtag interactions against each peptide target. Wild-type RPtag 
was screened as described in Section 3.3.4 in single replicate. Dashes indicate curve fittings 







3.6 Confirmation of Beneficial RPtag Mutants for VEGFR-1(229-251) and PD-L1(189-199) 
 
 To confirm beneficial effects on affinity by RPtag mutants towards VEGFR-1(229-251) 
and PD-L1(189-199), selected mutants were rescreened in triplicate, following the same 
procedure as described in Section 3.3.4. The best performing RPtag mutants were rescreened 
against VEGFR-1(229-251) and PD-L1(189-199), illustrated by Figure 5. Wild-type RPtag 
displayed similar affinity towards VEGFR-1(229-251) and PD-L1(189-199), with calculated KD 
values of 326.3 ± 35.34 nM and 218.7 ± 15.76 nM, respectively. For PD-L1(189-199), RPtag-
K248D, RPtag-K273S, RPtag-L275D, and RPtag-M270F all improved binding affinity from the 
wild-type to 50-100 nM (Fig. 5b&c). As Lys 248 is distal to the C-terminal Met 270, Lys 273, and 
Leu 275, this suggests that binding of the peptide roughly follows the RPtag binding cleft (Fig. 
1b), evidenced by the spread of these key locations throughout the binding cleft, as opposed to 
a local cluster. Ultimately, these findings warrant combination of these mutants to engineer a 
high-binding anti-PD-L1(189-199) mutant. The beneficial effects on affinity that each individual 
single-point mutant may not be additive however, as up to this point, the combinatorial effects of 
more than one single-point RPtag mutation have not been evaluated. For VEGFR-1(229-251), 
the nearby Phe mutations RPtag-A257F and RPtag-I247F produced a similar effect on binding 
affinity, with respective KD values of 55.75 ± 3.088 nM and 34.07 ± 2.279 nM (Fig 5a&c). In 
addition to their proximity, the similar affinities produced by both A257F and I247F suggest 
interaction with a common residue on VEGFR-1(229-251), and that a combination of both may 
not produce an additive effect on affinity. RPtag-F137K and RPtag-K248D demonstrated slight 
improvements in affinity compared to the wild-type (KD = 220.1 ± 15.20 nM and 167.1 ± 9.042 


















Figure 5. Rescreen of selected RPtag mutants against VEGFR-1(229-251) and PD-L1(189-
199). (a) RPtag-A257F (purple diamonds), RPtag-F137K (pink inverted triangles), RPtag-I247F 
(green triangles), RPtag-K248D (light purple squares), and the wild-type (black circles) were 
titrated against rhodamine labeled VEGFR-1(229-251). (b) RPtag-K248D (pink inverted 
triangles), RPtag-K273S (green triangles), RPtag-L275D (purple diamonds), RPtag-M270F (light 
purple squares), and the wild-type (black circles) were titrated against rhodamine labeled PD-
L1(189-199). (c) Summary of calculated KD values with standard error for each titration in (a) 
and (b). Data shown is mean ± SE, n = 3 and was fitted to a nonlinear four-parameter 




3.7 Engineering High-Affinity RPtag Mutants towards PD-L1(189-199) and VEGFR-1(229-251) 
 
 To further improve affinity towards VEGFR-1(229-251) and PD-L1(189-199), RPtag 
mutants were designed which combined high affinity mutants from screening up to this point. 
High affinity mutants were chosen which caused an apparent increase in affinity towards the 
respective ligand, as well as several which did not appreciably change affinity, but increased 
chemical diversity of the binding cleft thus affecting specificity. Ultimately, the purpose of these 
experiments was to rapidly evaluate the effects caused by multiple mutations, and to use this 
data to propose high-affinity RPtag mutants towards both targets. Additionally, the results from 
this screen further demonstrate the tunability of the RPtag scaffold towards different epitopes, 
highlighting its potential as a novel, non-antibody scaffold that can bind targets with high affinity.  
All mutants were expressed as previously described under Materials and Methods. 
Figure 7 illustrates the results of the combinatorial screen, with the highest affinity variants, 
denoted by asterisks, shown as inset figures. For PD-L1(189-199), RPtag-
K273S_K276A_K248D_M270F drastically increased binding from the wild-type with a KD = 
12.54 nM 95% CI [11.46, 13.74], representing a 14-fold increase in affinity from the rescreened 
wild-type (KD = 179.6 nM 95% CI [159.0, 204.4]), and an 8-fold increase in affinity from RPtag-
K273S (Fig. 6a). In general, each combination of mutants had a positive effect on affinity from 
the D,K,S,F series of single-point mutations carried out on the RPtag binding cleft. RPtag-
K273S_K276A_K248S represented the lowest affinity mutant from this generation of mutants, 
with a KD = 33.18 nM 95% CI [30.27, 36.42], which still represents a marked increase in affinity 
in comparison to mutants from the D,K,S,F generation. Represented by RPtag-
K273S_K276A_K248D_M270F, each combinatorial RPtag mutant bound PD-L1(189-199) with 
high specificity, indicated by a saturable limit occurring at 10-100 nM of binding protein. Each 
combinatorial RPtag mutant contained K273S (Fig. 5b) and K276A, identified previously, and 
63 
 
apart from RPtag-K273S_K276A_K248S, each mutant also included K248D (Fig. 5b). 
Ultimately, this allowed for evaluating any additional effects caused by A257D, G130D, K129F, 
L244D, L266F, M270F, V120D, or Y274D. Although any compounding effects from these 
mutations were not evaluated in this screen, the proximity and types of mutations could inform 
design of high-affinity variants, as shown in Figure 1b. K273S is proximal to L275D, V120D, and 
Y274D, and their chemical differences suggest compatibility with one another. The proximity 
between L275D, V120D, and Y274D suggests interaction with a similar positively-charged 
region on the peptide, which may be enhanced by any combination of the three. Similarly, 
M270F and L266F are essentially adjacent and may compete for the same residue(s) on the 
epitope, should they be incorporated on a single mutant. In the case of pi-stacking interactions 
with nearby aromatic residues however, this may prove beneficial.7 K248D, A257D, and L244D 
are similarly proximal near the N-terminus of the protein and are likely interacting with an 
additional positively-charged region. G130D and K129F are proximal, and due to their chemical 
differences, are likely interacting with different polar and hydrophobic residues, respectively. 
For VEGFR-1(229-251), RPtag-I247F_A257F_L275D provided the highest change in 
affinity, decreasing the KD of RPtag towards the peptide by two orders of magnitude (KD = 3.899 
nM, 95% CI [3.747, 4.058]), representing a 79-fold increase in affinity from the rescreened wild-
type (KD = 307.3 nM 95% CI [271.2, 351.9], Fig. 6b). All RPtag mutations contained I247F (Fig. 
5a), either A257F or F137K, and one of the following: K273F, K276F, L275D, or V120D. Like 
the RPtag mutants designed against PD-L1(189-199), all mutations increased affinity from the 
D,K,S,F generation of mutants, but mutants containing A257F anecdotally increased affinity 
more than those containing F137K. Because of this increase, the combination of I247F with 
A257F is likely beneficial by itself, which is of note due to the proximity of both residues to one 
another. Likely, both I247F and A257F are interacting with the same hydrophobic region on the 
VEGFR-1(229-251) sequence. F137K also appears to increase affinity in conjunction with 
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I247F, and inclusion of all three mutants for future RPtag variants may be beneficial. For the 
same reasons as with PD-L1(189-199), L275D and V120D may have positive impacts on 
affinity, and could be combined with the distant K248D (Fig. 5a) to improve binding in addition to 
I247F, F137K, and A257F. Finally, K273F and K276F could be included as a hydrophobic-
promoting region which is opposite on the binding cleft to the I247F binding region. While not 
necessarily additive, inclusion of each or several of the mutants described here may have a 
positive impact on RPtag binding affinity. Ultimately, future screening would require pinpointing 
the combinatory effects of nearby, chemically-similar mutations, as well as choosing positions 




 The affinity of RPtag towards PD-L1(189-199) and VEGFR-1(229-251) was increased by 
approximately 14-fold and 79-fold, respectively. For PD-L1(189-199), RPtag-
K273S_K276A_K248D_M270F bound with KD = 12.54 nM 95% CI [11.46, 13.74], substantially 
tighter than the wild-type RPtag with KD = 218.7 ± 15.76 nM. For VEGFR-1(229-251), the 
change in affinity spanned almost two orders of magnitude, with RPtag-I247F_A257F_L275D 
binding with KD = 3.899 nM 95% CI [3.747, 4.058], compared to wild-type RPtag with KD = 326.3 
± 35.34 nM. Ultimately, the substantial increases in affinity by RPtag-
K273S_K276A_K248D_M270F and RPtag-I247F_A257F_L275D towards PD-L1(189-199) and 
VEGFR-1(229-251), respectively, demonstrate the effectiveness of the limited site-directed 
approach taken here in combination with rational engineering. 


















Figure 6. Summary of RPtag combinatorial mutant screen against (a) PD-L1(189-199) and (b) VEGFR-1(229-251). KD values for 
each RPtag combination mutant were determined using fluorescence anisotropy as previously described in Materials and Methods.  
Each RPtag mutant was screened in 24-point triplicate. Data shown is calculated KD with error bars representing 95% CI. Data for 
RPtag-K273S (green) and RPtag-I247F (green) is from Figure 6. Inset figures represent highest affinity RPtag variants, which are 
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CHAPTER 4: EVALUATING INTERACTIONS BETWEEN RPTAG AND RECOMBINANT PD-L1 




At this stage, RPtag has been engineered to bind PD-L1(189-199) and VEGFR-1(229-
251) peptides with relatively high affinity and specificity, but binding has not been observed with 
recombinant targets bearing the structure of the native proteins. To robustly evaluate the extent 
to which RPtag would bind these recombinant targets, significant considerations need to be 
given to protein expression and purification, characterization, and assay development. Here, 
such considerations might include optimization of expression systems to incorporate relevant 
post-translational modifications, purification schemes and stability studies to maintain proper 
protein conformation, development of methods for quantitative kinetic analyses, and designing 
assay controls which confirm proper protein conformation and activity. As the resulting amount 
of experimental design and optimization required for a truly robust analysis is outside the scope 
of this thesis, I instead conducted a preliminary investigation using Surface Plasmon Resonance 
(SPR) to qualitatively evaluate binding between RPtag-K273S_K276A_K248D_M270F and 
recombinant PD-L1. In further detail, I describe the drawbacks of my approach, and describe 
optimizations needed for quantitative SPR analyses. I also describe the in vivo mechanisms of 
the PD-L1/PD-1 interaction as it relates to immunosuppression, and the biophysical 
mechanisms responsible for successful PD-L1/PD-1 disruption. Finally, I discuss implications of 








 Fluorescence polarization is an informative technique for analysis of biophysical 
interactions between protein targets and peptide ligands, and in some instances, can be applied 
to larger protein-protein interactions.1,2 For determining steady-state affinity between relatively 
large proteins, special consideration must be given to selecting reporter fluorophores with 
sufficient excited-state lifetimes, as described in Sections 1.5.1-1.5.3. While possible with the 
use of ADOTA/KU560 dyes3, this requires covalent modification of one or both binding partners 
which may adversely affect the interaction. Whereas the N-terminal linkage of fluorophore onto 
growing peptide chains was highly amenable to workflows in Chapters 2 and 3, using site-
specific fluorophore conjugation for investigating recombinant protein binding would require 
extensive optimization, and would not provide the same degree of sensitivity seen with earlier 
FP screens. For site-specific linkages, modified expression systems are used to insert non-
canonical residues, often which are amenable to Copper(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) reactions.4,5  
Considerations must be given to optimal fluorophore placement, and labeling of both 
proteins in separate experiments is desirable to confirm anisotropy results. Additionally, the 
range of mass changes due to binding of two proteins > 20 kDa in size would likely result in 
decreased assay sensitivity, due to the constraints of fluorescence lifetime and cargo size 
(Sections 1.5.1-1.5.3). Even with a fluorophore having a long excited-state lifetime, a net 
polarization change due to a larger protein-protein interaction would still be of lesser magnitude 
than one caused by binding between a small peptide and a relatively large protein (Fig. 2, 
Chapter 1). While theoretically feasible, design of an FP-based experiment to investigate 
RPtag/PD-L1 binding would require significant optimization at the expression, purification, and 
assay development levels.  
69 
 
 To avoid extensive optimization, provide increased sensitivity with respect to FP, and 
observe real-time kinetics about the RPtag/PD-L1 interaction, Surface Plasmon Resonance 
(SPR) was used for analysis with the recombinant protein. Unlike FP, SPR allows for real-time 
measurement of mass changes due to binding interactions, thus allowing for determination of 
both the kinetic rate constants (ka and kd) as well as affinity (KD). As a secondary assay 
measure, SPR also gives insight into the quality and concentration of active protein, and as 
demonstrated further in this chapter, clearly differentiates 1:1 binding, multivalency, and non-
specificity from one another.   
 
4.3 Applications of Surface Plasmon Resonance (SPR) for Macromolecular Interactions 
 
 4.3.1 Theory and Uses of SPR 
 
In theory, SPR relies on the principles of the attenuation of light due to changes in 
plasmon resonance.6–8 Polarized light which is emitted from a lamp collides with a glass prism 
on one side of a gold chip. This excites surface plasmons, or oscillations of excited surface 
electrons, on either side of the gold surface. The other side of the gold chip, which is not 
covered by a glass prism, is typically functionalized with chemical handles (i.e. dextran) which 
allow for covalent linkage of ligands of interest. Mass changes that occur at or near the 
functionalized surface of the gold chip, such as binding or dissociation of analytes with the 
immobilized ligands, affects the reflection angle of emitted light on the opposite side, thus 
providing a quantitative metric which is solely dependent on mass changes or depositions near 
the chip surface.  
SPR is particularly well-suited to study protein-protein interactions from a biophysical 
perspective. SPR is a label-free technique, as it does not require the use of fluorophores or 
other reporter molecules for analysis. As the attenuated light does not encounter the solution 
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however, the spectroscopic properties of the analysis solution(s) do not interfere with the assay. 
In other words, SPR is compatible with fluorophore-conjugates, intrinsically-fluorescent 
macromolecules, and highly-colored solutions. Since mass changes are measured in real-time, 
steady-state equilibrium is not required to accurately determine kinetic and affinity constants.9 In 
recent years, commercially-available SPR devices have enjoyed substantial increases to 
sensitivity and resolution, and often outcompete orthogonal techniques in these areas.7,10 SPR 
has been used to study a myriad of interactions in a multitude of formats, including small 
molecule disruption of protein-protein interactions,11,12 protein-protein kinetics and affinity,12–14 
surrogate potency for clinical mAbs and other biologics,15 binding to G-protein coupled receptors 
(GPCRs) and other membrane proteins,10 epitope binning,16 development of bi-specific 
antibodies,17 high-throughput screens (HTS) of small molecule fragments,18 binding analyses 
performed in complex bioliquids including sera and un-purified lysates19, and whole-cell 
analyses of surface receptors using live virions or pathogens.20 Combined with low sample 
consumption and compatibility with virtually any buffer, applicability towards a wide variety of 
experimental designs makes SPR a versatile technology for macromolecular analysis.8 
 
4.3.2 Considerations for Assay Development 
 
A typical SPR experiment for evaluating protein-protein interactions involves (1) covalent 
immobilization or capture of a receptor or binding protein (a.k.a. ligand) onto the glass-coated 
gold chip surface, (2) equilibration of the chip surface with buffer, (3) injection of binding partner 
(a.k.a. analyte) in buffer over the immobilized ligand, which is followed by (4) injection of running 
buffer, thus allowing for (5) analyte dissociation from the ligand. Throughout all steps (1-5), 
mass changes on the chip surface are continuously monitored in real-time. As changes in 
solution affect ligands and binding partners (i.e. stability, folding), which is dependent on the 
stability of the immobilized ligand and its ability to spontaneously refold, regeneration can occur 
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with short injection(s) of denaturing and/or cleaning agents such as detergents or salts, thus 
removing any unbound analyte and returning the system back to baseline. Figure 1 illustrates 
SPR sensorgrams for several concentrations of a peptide analyte over an immobilized protein 
ligand, which is known to bind the peptide with ~10-7 M affinity. Here (Fig. 1a), each 
concentration (i.e. each curve, top-to-bottom) reaches steady-state, indicating a specific and 
saturable interaction which is not hindered by diffusion or mass-transport limitations (MTL). It is 
important to note, however, that none of the concentrations in Figure 1a display ligand 
saturation, which is observed when increasing concentrations of injected analyte no longer 
increases the response. Reaching steady-state is essential for reliable affinity fitting as seen in 
Figure 1b, but an interaction which does not completely reach steady-state will not necessarily 
prevent reliable sensorgram fitting. For determining kinetic rate constants ka and kd (kon and koff), 
exponential models are fitted to both the association and dissociation phases (indicated in Fig. 
1a). The quality of the fit is not entirely dependent on reaching steady-state equilibrium but 
largely depends on the length of both association and dissociation phases, which becomes 
especially true in the case of proteins such as antibodies with extremely long dissociation times 
(kd ~ 10-5).15,19,21 Quantitative metrics for evaluating the quality of fit include chi-square, 
indicating goodness-of-fit, and residual plots, which show the difference between data points 
and the fit.7,8 In general, high-quality fitting is indicated by residual plots which show noise and 
no clear trends.8 To robustly confirm the quality of the experiment, however, orthogonal assays, 
replicates, and separate experiments and/or formats (e.g. reversing ligand and analyte) should 
be performed. Additionally, non-specificity, sample impurities, mass-transport limitations, and 
ligand immobilization levels all play a part in the quality of the fit, and can prevent quantitative 




 Ligand immobilization levels directly influence the theoretical maximal response (Rmax) 
for an analyte. In turn, this influences the extent to which mass-transport limitations affect 
binding, and ultimately, the quality of the experiment. The relationship between ligand 
immobilization (RL) and Rmax is given by the Rmax equation for a 1:1 binding interaction: 
𝑅𝑚𝑎𝑥 =  
𝑀𝑊𝐴
𝑀𝑊𝐿
∗ 𝑅𝐿                                                                           (1) 
where MWA and MWL are the molecular weights of the analyte and ligand, respectively7. Thus, 
higher ligand immobilization will give a higher Rmax value. For accurate kinetic analyses, Biacore 
systems recommend keeping Rmax < 100 RU, and often down to 10-20 RU when possible. In 
addition to eliminating mass-transport limitations near the chip surface, keeping a low 
immobilization of ligand minimizes rebinding of the analyte during dissociation, and has the 
added benefit of minimizing the amount of sample needed. Even after optimizing SPR assay 
conditions, however, poor quality data can still be obtained. In such cases, as is demonstrated 
later in this chapter, the issue may partly arise from sample impurities or denatured/misfolded 
proteins. Section 4.4 highlights one particular technique, Differential scanning fluorimetry or 














Figure 1. Representative titrations of serially-diluted concentrations of peptide with immobilized binding protein. (a) Annotated 
sensorgrams for 1.55 µM peptide (black), 777 nM peptide (orange), 388 nM peptide (purple), 194 nM peptide (green), 97.1 nM 
peptide (red), and 48.5 nM peptide (blue). Sensorgrams for two concentrations, 3.10 µM and 6.21 µM, were omitted from this plot but 
taken into account for calculation of affinity and rate constants. Black bars indicate reporting points which are used to calculate 
steady-state affinity. Fitting lines are not shown. (b) KD determination from steady-state affinity. Relative response indicates response 
at each reporting point in (a). Vertical dashed line indicates calculated KD. (c) Comparison of calculated rate and affinity constants 
from sensorgram fitting (a) and calculated affinity constant from (b). Sensorgrams were fitted using Biacore 8K Evaluation Software, 
and steady-state affinity was fitted using a four-parameter non-linear regression in GraphPad Prism 8.   
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4.4 Differential Scanning Fluorimetry for Evaluating Protein Conformation 
 
 Differential scanning fluorimetry (DSF, also known as Thermal Shift Assay or TSA) 
makes use of the SYPRO Orange Dye, which non-specifically binds hydrophobic surfaces that 
primarily reside in interior, solvent-inaccessible ‘pockets’ of structured proteins. SYPRO dye is 
strongly quenched in aqueous solutions, and thus, will only emit a measurable fluorescent 
signal when bound to proteins or other hydrophobic surfaces.22 As most folded proteins have 
predominantly hydrophilic exteriors and hydrophobic interiors,23,24 folded proteins will not 
strongly bind SYPRO dye, and thus, the fluorescent readout will be low. A shallow temperature 
gradient is applied samples containing SYPRO dye and the protein(s) of interest, and 
fluorescent readout is measured as a function of temperature. As the temperature increases 
and the protein sample(s) begin to denature, the SYPRO dye has greater access to interior, 
hydrophobic regions, resulting in an increase in fluorescence.25 The fluorescent signal will 
maximize when the protein achieves a completely denatured state, and will subsequently 
diminish with increasing temperature as the dye begins to dissociate from hydrophobic regions.  
For ideal, globular proteins with stability at room temperature, this creates a sigmoidal 
curve, with the infection point of the curve representing the melting temperature, or Tm, of the 
protein. After the maximum response is reached and the dye begins to dissociate from the 
protein, signal will diminish with increasing temperature. The Tm is useful for determining 
changes in protein stability due to buffers, stabilizing ligands, and/or interacting partners. The 
measured Tm of a protein will increase as its stability increases.22 Factors affecting protein 
stability may include pH, salt concentration, binding partners and/or stabilizers, detergents, 
reducing agents, and even other proteins, most of which are generally compatible with DSF.26 A 
high background signal at low temperatures indicates that the SYPRO dye is binding solvent-
accessible hydrophobic regions on the protein, which may indicate a denatured sample. Finally, 
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and of relevance here, increases in signal at temperatures lower than the maximum response 
generally indicate disruption of secondary and tertiary protein structures.  
 
4.5 PD-L1 as an Immunomodulatory Drug Target for Cancers 
 
 Up to this point, little mention has been made of the in vivo mechanisms for the 
screened targets, nor of the current consensus on each of these targets. As the work presented 
here has primarily focused on target screening, mutagenesis, and rational design from the 
standpoint of RPtag, the scientific consensus and therapeutic relevance of each target has not 
been discussed. In this section, the reasons for why PD-L1 was slated as a preferable target for 
SPR binding studies, as opposed to VEGFR-1, is discussed. 
The PD-1/L1 interaction is a well-characterized immunoinhibitory signal that is 
constitutively expressed in many immune, epithelial, and vascular endothelial cells.27–31 Antigen-
presenting cells (APCs) which are exposed to cytotoxic or inflammatory signals will express PD-
L1, which upon binding PD-1 receptors on nearby regulatory T-cells (Treg), will decrease the 
proliferation of T-cells, thus attenuating the local immune response.27,28,32 Often in conjunction 
with other immunomodulatory signals such as CD80, the PD-1/L1 pathway serves as a critical 
negative immune checkpoint for normal cell function.33 However, the pathway can become 
insidious for patients with advanced and/or metastatic cancers. Many cancerous cells have 
evolved to evade T-cell mediated cytotoxicity by overexpressing PD-L1.34–36 Overexpression of 
PD-L1 on tumors sends consistent signals to nearby Treg cells to slow T-cell proliferation, which 
over time, creates an immunosuppressive microenvironment near the malignancies. 28,33 
Ultimately, PD-L1 overexpression allows cancers to effectively avoid the T-cell mediated host 
immune response. Clinically, immunoevasion of advanced cancers can rapidly deteriorate a 
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patient’s prognosis, resulting in the formation of new metastases and proliferation of existing 
tumors.27,35  
To selectively target immunoevasive cancers, immune checkpoint blockade therapies, 
which broadly involve the reactivation of the host’s immune system in the tumor 
microenvironment, have appeared on the market over the past several decades. To date, three 
anti-PD-L1 mAbs have been approved for clinical use for treating various cancers, in addition to 
two anti-PD-1 mAbs. These biologics and their indications are summarized by Table 1. 
Avelumab, atezolizumab, and durvalumab have all been shown to tightly bind the PD-1 
interacting region of the ligand, thus preventing T-cell repression from activation of the PD-1/L1 
interaction and lessening host immune suppression, thus improving clinical prognoses.36–38 
Underactivation of the PD-1/L1 pathway can cause severe complications as well. Autoimmune 
diseases including lupus and arthritis have been implicated with high levels of PD-1/L1 
disruption.39 Hence, balance of the PD-1/L1 axis is critical for maintaining proper T-cell function 
while simultaneously avoiding pathological autoimmunity. While commercially-available mAb 
therapies have proven to be quite effective in treating PD-L1 overexpressing tumors, none of 
these therapies, to date, demonstrate the same hyperstability observed with RPtag, nor have 
they been made into an orally-bioavailable formulation. For these reasons, in addition to the 
lower cost of production associated with RPtag, PD-L1 was chosen as the focus for the 




Name Brand Name Manufacturer Target Cancer Indication(s) Date of First Approval (US) 
Atezolizumab Tecentriq Genentech PD-L1 
Hepatocellular, Melanoma, Non-Small and Small 
Cell Lung, Triple-Negative Breast, Urothelial40 
May 2016 
Avelumab Bavencio EMD Serono PD-L1 Gastric, Urothelial, Merkel-Cell41 March 2017 





Colorectal, Esophageal, Hepatocellular,  Head & 
Neck, Hodgkin's Lymphoma, Melanoma, Renal 
Cell, Non-Small and Small Cell Lung, Urothelial43 
December 2014 
Pembrolizumab Keytruda Merck PD-1 
Cervical, Endometrial, Esophageal, Gastric, Head 
& Neck, Hepatocellular, Hodgkin's Lymphoma, 
Merkel Cell, Melanoma, Non-Small and Small Cell 
Lung, Renal Cell, Squamous Cell, Urothelial44 
September 2014 
 
Table 1. List of clinically-approved PD-1/L1 inhibitors in the United States as of August 2020. 
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4.6 Materials and Methods 
 
 4.6.1 Recombinant Expression and Purification of PD-L1(18-239) 
 
 For recombinant expression of PD-L1(18-239), BL21(DE3) E. coli cells were transformed 
with a pET28a(+) vector containing a 8H-LEVLFQ/GP-PD-L1(18-239) construct (PreScission 
Protease cleavage site) and grown, harvested, and centrifuged as described in Chapter 2, 
Materials and Methods. Protein was contained in inclusion bodies in the cell pellet, and was 
extracted using denaturing conditions: 50 mL cell pellets were resuspended in 50 mM sodium 
phosphate, pH 7.4 buffer containing 300 mM NaCl, 20 mM imidazole, 10 mM βME and 6 M 
guanidine HCl, and ultrasonicated for 10 minutes. Lysate was added to 40 mL equilibrated Ni-
NTA resin in a 1 L centrifuge bottle, which was previously washed with 5 RBV of the buffer. The 
column was washed with 5 RBV of the buffer, and fractions were collected. The column was 
then washed again with 5 RBV of 50 mM sodium phosphate pH 7.4 with 300 mM NaCl, 20 mM 
imidazole, 10 mM βME to promote refolding. For elution of His-tagged PD-L1(18-239), the 
column was washed with 5 RBV of 50 mM sodium phosphate pH 7.4 with 300 mM NaCl, 300 
mM Arginine-HCl, 5% (v/v) glycerol, 400 mM imidazole, 10 mM βME and fractions were 
collected. PD-L1(18-239) containing fractions were pooled (fractions E4-E8, Fig. 2a) as 
determined by SDS-PAGE using Coomassie Brilliant Blue R250 and were purified via SEC (Fig. 
2c) using a Superdex 75 Increase 10/300 GL column at a flow rate of 0.40 mL/min using 50 mM 
sodium phosphate pH 7.4 with 300 mM NaCl, 200 mM Arginine-HCl, 5% (v/v) glycerol, 10 mM 
βME for an elution buffer. PD-L1(18-239) containing fractions were determined via SDS-PAGE 
and pooled (fractions A28-A33, Fig. 2b), flash frozen in liquid N2, and stored at -80°C until use. 
Due to the formation of inclusion bodies, site-specific cleavage of the N-terminal 8xHis tag from 
PD-L1(18-239) could not occur. The same batch of RPtag mutant(s) that were used in Chapter 




4.6.2 SPR Assays Using PD-L1(18-239) and RPtag Mutants 
 
For kinetic and affinity analyses between RPtag variants and PD-L1(18-239) using the 
Biacore 8K, RPtag, RPtag-K273S_K276A_K248D_M270F, and RPtag-
K273S_K276A_K248D_L275D were each immobilized onto one lane on a Series S CM4 
Sensor Chip using a 1:1 N-hydroxysuccinimide (NHS):1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) ratio. Following a 420 s NHS/EDC activation, 30 
µg/mL protein in 10 mM sodium acetate buffer at pH 4.0 with 50 mM NaCl was immobilized on 
the activated chip surface for 420 s, followed by a 420 s ethanolamine deactivation. All 
immobilization steps were performed at a flow rate of 10 µL/min. 12.0 µM PD-L1(18-239) from 
SEC elution was titrated in a 2-fold, 5-point dilution to 750 nM, using the SEC elution buffer for 
dilutions and as a running buffer (50 mM sodium phosphate pH 7.4, 300 mM NaCl, 200 mM 
Arginine-HCl, 5% (v/v) glycerol, 10 mM βME). Titrated PD-L1(18-239) was analyzed using a 
multi-cycle kinetics format against the three RPtag variants at a flow rate of 30 µL/min with 360 
s association and a 600 s dissociation period followed by regeneration using 6M guanidine HCl 
for 120 s at 10 µL/min, followed by a 180 s, 30 µL/min re-equilibration of the chip surface with 
running buffer. Prior to the first analysis, 5 blank running buffer injections were performed 
including regeneration and re-equilibration. For analyses and immobilization, flow cell 
temperature was kept at 25°C and all samples were kept at 5°C. Analysis of PD-L1(18-239) with 
the knockout mutant RPtag-A254F and RPtag-K273S_K276A_K248D_M270F were performed 
in the same manner, with the sole exception that 10 mM βME was not included in the running 
buffer. For data analysis, curve data was taken from the Biacore 8K Evaluation Software and 
plotted separately in GraphPad Prism 8. The PD-L1(18-239) structure in complex with PD-1(24-






















Figure 2. Purification of recombinant 8H-PPase-PD-L1(18-239) (28.7 kDa, including 8H tag and 
PPase cleavage site). (a) SDS-PAGE gel from Ni-NTA purification. b) SDS-PAGE gel from 
SEC. (c) SEC chromatogram for purification of 8H-PPase-PD-L1(18-239). Dashed lines in (c), 







4.6.3 Dialysis and DSF Analysis of PD-L1(18-239)  
 
For DSF/Thermal Shift Assay of PD-L1(18-239) before and after dialysis, 2 mL of 12.0 
µM 8H-PPase-PD-L1(18-239) from SEC elution was dialyzed twice for 4-8 hours at 2-8°C into 
50 mL of dialysis buffer in a 10 kDa MWCO Slide-A-Lyzer dialysis cartridge: 50 mM sodium 
phosphate buffer at pH 7.4 containing 300 mM NaCl, 200 mM Arginine-HCl, with 5% (v/v) 
glycerol. 25 µL of undiluted protein before and after dialysis was added to 10 µL 50X SYPRO 
Orange dye and 15 µL of SEC elution buffer or dialysis buffer, respectively, in triplicate on a 96-
well PCR plate and analyzed using the QuantStudio 3 Real-Time PCR instrument, using 
Thermal Shift Assay Software and pre-programmed settings for stability studies. A temperature 





All SPR assays were performed on a Cytiva Biacore 8K (Marlborough, MA). Series S 
CM4 chips and the Superdex 75 Increase 10/300 GL column for SEC purification were also 
purchased from Cytiva. Differential scanning fluorimetry experiments were performed using an 
Applied Biosystems QuantStudio 3 Real-Time PCR Instrument using Applied Biosystems 96-
well PCR plates and plate seals (Foster City, CA). Ultrapure water was used for all 
buffers/dilutions for SPR assays, and was obtained in-house from a Milli-Q system (Millipore 
Sigma, Burlington, MA). Isopropyl-β-d-1-thiogalactopyranoside (IPTG) was purchased from 
Gold Biotechnology (St. Louis, MO). All expression plasmids were synthesized, codon 
optimized, and sequence verified by GenScript (Piscataway, NJ). Untreated 96-well 
polypropylene microplates were purchased from Corning (Corning, NY). All other reagents and 





4.7.1 Initial Multi-Cycle Kinetics with High-Affinity RPtag Mutants and PD-L1(18-239) 
 
 RPtag-K273S_K276A_K248D_M270F and RPtag-K273S_K276A_K248D_L275D bound 
PD-L1(18-239) in a dose-dependent manner, shown in Figure 3. Based on the quality of the 
data obtained from the preliminary experiments, quantitative and definitive data analyses could 
not be performed. Most importantly, the high immobilization levels (RL > 1000 RU) for all three 
RPtag mutants may be causing non-specific binding to occur between the ligand and analyte, 
which is evidenced by the gradual increase in response just prior to dissociation (Fig. 3a & b). 
Additionally, rebinding of PD-L1(18-239) to RPtag-K273S_K276A_K248D_L275D may be 
occurring, as shown by the increase in response during the dissociation phase (Fig. 3c). This is 
unlikely to be solely a result of baseline drift, however, as there is only a 2% decrease in the 
baseline response for each channel between the first and last analysis cycles (data not shown). 
This suggests that regeneration of the immobilized RPtag mutants with 6M guanidine-HCl is 
sufficient for removing bound PD-L1(18-239), and results in only minor decreases in activity on 
the chip surface. While determining the extent to which specific factors are influencing the 
sensorgram shapes in Figure 3 is difficult, the high immobilization levels are also likely causing 
mass transport limitations near the chip surface.  
 Importantly, none of the tested concentrations of PD-L1(18-239) reached steady-state, 
which strongly suggests that non-specific binding is occurring between both RPtag-
K273S_K276A_K248D_M270F and RPtag-K273S_K276A_K248D_L275D, and PD-L1(18-239). 
While the RPtag mutants may bind properly-folded PD-L1(18-239) in a truly non-specific 
manner, the sensorgrams in Figure 3b and 3c indicate that there is a very low concentration of 
active PD-L1(18-239) at the chip surface. Although RPtag wild-type had little affinity towards the 
analyte, and possibly experienced errors due to buffer mismatch or baseline drift, both RPtag-
K273S_K276A_K248D_M270F and RPtag-K273S_K276A_K248D_L275D show biphasic 
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binding profiles towards the PD-L1(18-239) (Fig. 3b & c). A biphasic profile is evidenced by 
having four distinct periods: a quick jump in response followed by a slow on-binding, and a quick 
drop in response indicating a quick dissociation, and finally a slow off phase which does not 
return to baseline for any concentration. Whereas a truly weak (i.e. slow ka) or non-specific 
interaction would show only a gradual, non-saturating response during association, the biphasic 
profile observed in the sensorgrams from Figure 3b and 3c are likely the combination of multiple 
binding phenomena, between both folded PD-L1(18-239) (i.e. causing a quick, specific 
response), and misfolded/denatured PD-L1(18-239) (i.e. causing the slow, non-specific on-
binding). Misfolding of the PD-L1(18-239) is likely a result of the inclusion of reducing agents 
throughout the purification process and within this analysis. Misfolding may also be the result of 
denaturing conditions used to extract the protein from inclusion bodies, or even a combination of 
the two conditions. There are two structural disulfides within the PD-L1(18-239) structure, 
evidenced by Figure 4, and the accidental disruption of these may be responsible for non-
specific binding with the RPtag mutants. The proximity of the disrupted Cys 155 – Cys 209 
bridge to the PD-L1(189-199) epitope (Fig. 4) almost certainly affects the local structure, and 
thus binding of RPtag to this epitope. Thus, the biphasic nature of the sensorgrams may be 
explained by a combination of non-specific binding between misfolded analyte and RPtag, as 
well as some degree of specific binding occurring at the PD-L1(189-199) epitope. In simple 
terms, these sensorgrams are likely the culmination of misfolded PD-L1(18-239) and the effects 











Figure 3. Preliminary SPR experiments between recombinant PD-L1(18-239) and (a) RPtag wild-type, (b) RPtag-
K273S_K276A_K248D_M270F, and (c) RPtag-K273S_K276A_K248D_L275D. Ligand immobilization levels (RL) for the respective 
channel are shown, in addition to the theoretical Rmax values as calculated using the Rmax equation (Equation 1). For all three 
channels, five concentrations of PD-L1(18-239) were tested: 12.0 µM (blue), 6.00 µM (red), 3.00 µM (green), 1.50 µM (purple), and 




4.7.2 Evaluation of PD-L1(18-239) Stability Using DSF 
 
To determine if PD-L1(18-239) stability could be recovered, reducing agent was 
removed by double dialysis and analyzed using DSF. Figure 5 shows the results of PD-L1(18-
239) from pre- and post-dialysis. While dialysis did not appear to increase the Tm of the protein 
to a measurable value, a clear, albeit small increase in fluorescence is observed in all three 
replicates of the post-dialysis PD-L1(18-239) between 25-30°C. This suggests the disruption of 
secondary or tertiary structures which were not present in the pre-dialysis sample, and thus, that 
the removal of βME improved stability. However, these results must be interpreted with caution, 
as an ideal, sigmoidal melt curve with a clearly-defined Tm shift was not observed. The relatively 
high background fluorescence (~150,000-200,000 RFU; Fig. 5) of every sample indicates that 
the tested PD-L1(18-239) was almost completely denatured at room temperature, and that any 
increase in stability due to the removal of βME at assay temperature is questionable at best. 
The sample which did not undergo dialysis clearly exhibited a denatured profile, as no 
appreciable increases in fluorescence were observed throughout the gradient. For the purposes 
of SPR analyses, which are performed at 25°C, the pre-dialysis thermal melt curves suggest 
that the active concentration of folded PD-L1(18-239) was low for the experiments performed in 
Figure 3. This would explain the biphasic nature of both RPtag-K273S_K276A_K248D_M270F 
and RPtag-K273S_K276A_K248D_L275D binding PD-L1(18-239): although a small amount of 
properly-folded PD-L1(18-239) was specifically binding RPtag, the interference of denatured 
analyte which bound the RPtag variants at a different on and off rate ultimately resulted in 
























Figure 4. Structure of human PD-L1(18-239), blue, in complex with mouse PD-1(24-157), 
orange. PD-L1(189-199) is highlighted in green, and PD-L1(126-134) is highlighted in pink near 
the center of the structure. Two disulfide bridges, Cys 40 – Cys 114 and Cys 155 – Cys 209 are 




















Figure 5. Fluorescent response vs increasing temperature for PD-L1(18-239) with (black, pre 
dialysis) and without (pink, post dialysis) 10 mM βME as measured by DSF/Thermal Shift 







4.7.3 PD-L1(18-239)/RPtag Binding Corroborates Fluorescence Polarization Experiments 
 
To evaluate if using PD-L1(18-239) in a non-reducing environment would improve kinetic 
analyses, RPtag-K273S_K276A_K248D_M270F was immobilized onto a new lane on the CM4 
chip, as well as RPtag-A254F, which previously exhibited no measurable activity against PD-
L1(189-199) by fluorescence anisotropy (Chapter 3, Fig. 4b). Figure 6 shows RPtag variant/PD-
L1(18-239) as measured by SPR and fluorescence anisotropy. Again, as none of the 
concentrations reach steady-state, and because of the high immobilization levels for RPtag-
K273S_K276A_K248D_M270F, quantitative and robust analyses cannot reliably happen. 
However, immobilization techniques here were performed in the same manner as before to 
allow for direct comparisons between the two experiments.  No measurable binding is observed 
with the knockout RPtag-A254F in both fluorescence anisotropy (Fig. 6c) and by SPR (Fig. 6b), 
and a dose-dependent response is again observed in the high-affinity mutant (Fig. 6a). This 
suggests that the RPtag-K273S_K276A_K248D_M270F is binding the PD-L1(189-199) epitope, 
and further confirms that the mutant is binding the recombinant PD-L1 with some specificity. 
These sensorgrams in Figure 6 are similar to those in Figure 4b and 4c, however: non-specific 
interactions are still present as indicated by a lack of response saturation, and a specific 
interaction with active PD-L1(18-239) is likely occurring simultaneously.  
While possible to design a workflow for expression and purification of PD-L1(18-239) 
that does not include reducing agents, these experiments are not within the scope of the work 
performed here. Even being unoptimized, the SPR experiments in this chapter qualitatively 
show that RPtag binds extracellular PD-L1(18-239) in a dose-dependent manner, and strongly 
correspond with the fluorescence anisotropy data, as represented by Figure 6. While 
disappointing that the KD between RPtag-K273S_K276A_K248D_M270F and PD-L1(18-239) 
could not be reliably calculated, the data shown here confirms that the mutant had engineered 
affinity against the protein, especially compared to the wild-type (Fig. 3). To obtain robust 
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kinetics, lower immobilization levels of RPtag mutants would need to be achieved, and a higher 
active concentration of PD-L1(18-239) would need to be present in the sample, which would 
ideally be achievable by excluding the use of reductants in the protein purification workflow. 
While possible that the PD-L1(18-239) screened in Figure 6 had greater activity than from 
Figure 4, it is highly plausible that the protein is unable to refold due to some combination of 
being disrupted with a high concentration of βME, having undergone one freeze-thaw cycle, and 
having been exposed to denaturing conditions from inclusion body extraction. Therefore, re-















Figure 6. RPtag-K273S_K276A_K248D_M270F and RPtag-A254F binding to PD-L1 as measured by SPR qualitatively corroborates 
fluorescence anisotropy data. Comparison of (a) RPtag-K273S_K276A_K248D_M270F and (b) RPtag-A254F binding kinetics 
towards PD-L1(18-239) after removal of βME. For both channels, five concentrations of PD-L1(18-239) were tested: 12.0 µM (blue, 
6.00 µM (red), 3.00 µM (green), 1.50 µM (purple), 750 nM (orange). (c) Affinities of RPtag-K273S_K276A_K248D_M270F (black) 
and RPtag-A254F (blue) towards rhodamine-labeled PD-L1(189-199) peptide as measured by fluorescence anisotropy. Data are 
mean anisotropy ± SEM, n = 3, and are fitted using a four-parameter non-linear fit in GraphPad Prism 8.
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4.8 Conclusions  
 
 The work presented in this thesis describes both a high-throughput approach to 
evaluating binding between novel binding protein and therapeutic targets, and shows how 
RPtag was specifically and rationally engineered towards PD-L1. Ultimately, the binding affinity 
of RPtag towards PD-L1(189-199) is increased by several orders of magnitude by RPtag-
K273S_K276A_K248D_M270F, and a clear dose-dependent binding of this high-affinity mutant 
towards extracellular PD-L1(18-239) is demonstrated. From a biophysical perspective, the 
experiments here show how RPtag can be further tuned towards PD-L1 to demonstrate higher 
affinity, and highlights the tolerance of the scaffold to mutational changes. Key amino acid 
residues in the RPtag binding cleft which were chosen for substitution substantially increased 
binding affinity towards PD-L1 with respect to the wild-type. Ultimately, this work warrants the 
further investigation of RPtag towards PD-L1 for the purpose of therapeutic development, while 
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Clarkson University, Potsdam, NY 
Chemistry, B.S. (Aug. 2014 – May 2018) 
Cumulative GPA: 3.51 
 
State University of New York College of Env. Science & Forestry (ESF), Syracuse, NY 
Biochemistry, MS (Aug. 2019 – Dec. 2020) 
Cumulative GPA: 3.96 
Nomura Research Group 
  
Work Experience 
WuXi AppTec, Inc., Research Service Division, In Vitro Biology Scientist I, Oct. 2020 – present, Cranbury, NJ 
• Developed novel orthogonal screening and hit-to-lead biophysical studies for clients using SPR 
• Designed and conducted experiments to determine biologic mechanisms of action, including protein-protein, 
protein-peptide, protein-liposome, protein-oligonucleotide, ternary complexes, hit validation & stoichiometry, 
and induced oligomerization 
• Wrote scripts using Python to accommodate compound library management and HTS in 384/1536-well 
format 
• Responsible for data presentation and client correspondence, and worked with clients to develop next steps 
Ichor Therapeutics, Inc. Research Technician, May 2018 – Aug. 2019, LaFayette, NY 
• Developed fragment-based screening methods for protein targets using SPR, and investigating hits using 
downstream dose-dependent and/or competition format experiments 
• Investigated binding and disruption of protein-protein and protein-peptide interactions using multi-cycle, 
single-cycle, and competition SPR experiments 
• Routinely performed SPR optimization experiments including immobilization, regeneration, and buffer 
scouting 
• Integrated liquid-handling robotics for use with SPR fragment-based screening methods to increase 
throughput 
• Developed a novel, regenerable, and repurposable SPR chip system employing a proprietary capture 
concept 
• Routinely used HPLC to characterize and purify small molecules and bioactive peptides 
• Synthesized, purified, and fully characterized bioactive peptides using Fmoc-based solid-phase peptide 
synthesis (SPPS) with characterization by RP-HPLC and MALDI-ToF; used in fluorescence polarization and 
SPR experiments 
• Developed methods for HPLC, MALDI-ToF, SPR, DSF, fluorescence polarization, and laboratory automation 
• Designed MATLAB algorithms to determine hits for a fluorescence polarization-based drug screen and 
investigated binding affinities of >5000 novel chemical entities for therapeutic targets 
Auctus Biologics, Inc. (Ichor Portfolio) Project Manager, Sep. 2018 – Jun. 2020, LaFayette, NY 
• Oversaw production, purification, and characterization of >100 recombinant proteins for use in downstream 
screening studies 
• Responsible for planning, execution, and iteration of studies, as well as relevant intramural communications 
and external collaborations  
• Worked closely with senior management to present experimental data and appropriately iterate protocols 
• Iterated high-throughput fluorescence polarization screens to develop biologics against recombinant 
therapeutically relevant targets 
• Optimized recombinant expression of antibody-like protein scaffold for bacterial surface display to be used in 
high-throughput magnetic-activated cell sorting (MACS) screens 
 
Undergraduate Experience 
Carbon Capture MOF Project, Advanced Laboratory, Clarkson University, Fall 2017 
• Successfully synthesized a reusable Cu(II) metal-organic framework (MOF) capable of adsorbing 
atmospheric CO2  
• Characterized MOF using single crystal XRD, TG, DSC, volumetric, and gravimetric gas adsorption 
96 
 
Summer NSF REU, Environmental Engineering Solutions for Pollution Prevention, University at Buffalo, Summer 
2016 
• Investigated formation of N-nitrosamines from amine mixtures in post-combustion carbon dioxide capture 
systems 
• Used UV-vis spectroscopy and HPLC to analyze samples 
• Developed a methodical approach to determine total nitrosamine concentration with the use of a novel NOx 
detection device 
Ferritin Research, Department of Chemistry and Biomolecular Sciences, Clarkson University, Fall 2016 
• Investigated therapeutic applications for ferritin based on responsiveness to pH changes 
• Loaded apoferritin with flavin mononucleotide molecules to simulate mechanism for pH-responsive drug 
delivery 
Clarkson University Potsdam, NY; ES100 (Introduction to MATLAB) Teaching Assistant, Spring 2016 
• Responsible for designing & proofreading lectures and test questions 
• Assisted students in and out of class 
 
Awards and Accolades 
Sigma Chi Horizons Leadership Summit Snowbird, UT; Summer 2016 
Eagle Scout Service Project, Rossie, NY; Summer 2013 
 
Skills and Interests 
Chromatography:  
• HPLC (Waters 2690/5 w/ 2996 PDA; Empower 3) 
• Flash Chromatography (Biotage Isolera) 
• FPLC (IMAC, IEX, SEC, Heparin, GST Affinity) (BioRad NGC) 
• UHPLC-MS (Sciex TripleTOF 6600; ThermoFisher TSQ Altis) 
Characterization: 
• UV-Vis Spectroscopy (several instruments) 
• DSF and RT-qPCR (QuantStudio 3) 
• Fluorescence and Fluorescence Polarization (SpectraMax i3) 
• Surface Plasmon Resonance (Biacore 8K; Biacore Evaluation Software) 
• MALDI-ToF-MS (Bruker autoflex iii) 
• ESI-MS (Waters Micromass Quattro Ultima) 
• FT-IR (several instruments) 
• NMR (1H, 1H-1H COSY, 1H-15N / 1H-13C HSQC, 13C/DEPT) (Bruker AVANCE III HD 800 MHz; AVANCE III 
600 MHz) 
Computer: MS Excel, Word and PowerPoint, Python, MATLAB, GraphPad Prism, PyMOL 
Other Biochemistry: PAGE, ELISA, recombinant expression in E. coli 
Automation: Biomek FX/P, Tecan Genesis, Opentrons OT-2 
 
 
 
 
 
 
 
 
 
 
